Antibodies binding b7-h3 and uses thereof

CN118900847APending Publication Date: 2024-11-05BEIJING MABWORKS BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280093350.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2022-03-18
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

Existing B7-H3 targeted therapies have limited effectiveness in cancer. Some patients show good response in the early stage but are prone to develop drug resistance in the later stage. Moreover, existing antibodies have deficiencies in binding specificity and ADCC effect, making it difficult to meet different characteristics. and drug efficacy characteristics.

Method used

Develop a new monoclonal antibody that binds to B7-H3 with high affinity, is endocytosed by B7-H3-positive cells, and has enhanced NK cell activation and antibody-dependent cell-mediated cytotoxicity ( ADCC) effect, the CDR sequences of the heavy chain variable region and light chain variable region have specific amino acid sequence variations, which enhance FcR binding and are modified to have enhanced ADCC effect.

Benefits of technology

The antibody shows significant binding activity and killing ability on B7-H3 positive tumor cells, can effectively activate NK cells and PBMC, significantly increase ADCC activity, delay or inhibit tumor growth, and provide stronger anti-tumor effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000044_0000
    Figure 00000044_0000
  • Figure 00000044_0001
    Figure 00000044_0001
  • Figure 00000044_0002
    Figure 00000044_0002
Patent Text Reader

Abstract

The invention provides a separated monoclonal antibody which specifically binds to B7-H3, or an antigen binding part of the monoclonal antibody. Also provided are nucleic acid molecules encoding the antibodies or antigen-binding portions thereof, as well as expression vectors, host cells and methods for expressing the antibodies or antigen-binding portions thereof. The present application also provides immunocrosslinkers, bispecific molecules, chimeric antigen receptors, oncolytic viruses and pharmaceutical compositions comprising the antibodies or antigen-binding portions thereof, as well as methods of treatment using the antibodies or antigen-binding portions thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Antibodies that bind to B7-H3 and their uses Technical Field

[0001] The present application relates to an antibody that specifically binds to human B7-H3, and its preparation and use, in particular, its use in treating B7-H3-related diseases such as cancer. Background Art

[0002] T cell proliferation and activation rely on two signals. The first signal, provided by the interaction between the T cell receptor and MHC-presenting peptides on the surface of antigen-presenting cells or tumor cells, is essential for T cell activation but does not induce cell proliferation or cytokine release. The second signal, the co-stimulatory signal, determines whether T cells activate, proliferate, become anergic, or undergo apoptosis. The B7-CD28 co-stimulatory pathway plays a crucial role in regulating T cell activation and inhibition. CD28 is expressed on T cells, while B7 is typically present on the surface of activated antigen-presenting cells. To date, over ten B7 protein molecules have been discovered and are categorized into three types based on the signals they transduce and their functions during T cell activation: I) co-stimulation; II) co-inhibition; and III) co-stimulation / inhibition.

[0003] B7-H3, also known as CD276, is a co-stimulatory / inhibitory molecule of the B7 family. When it was first discovered, it was considered a co-stimulatory molecule that promotes T cell activation and IFN-γ production. However, some recent studies have shown that B7-H3 has an inhibitory effect in adaptive immunity, such as inhibiting T cell activation, proliferation, and the release of effector cytokines (mainly IFN-γ and IL-2), and inhibiting the activity of NK cells (Prasad DVR. et al., (2004) J Immunol 173(4):2500–2506; Castriconi R. et al., (2004) Proc Natl Acad Sci USA 101(34):12640-12645). The seemingly contradictory regulatory effects of B7-H3 may be mediated by different receptors, but there are currently very few research results on B7-H3 receptors.

[0004] B7-H3 is a type I transmembrane protein that shares 20%-27% similarity with other B7 family members. It is encoded by a gene on chromosome 15q24 and structurally comprises an extracellular domain, a transmembrane domain, and a short intracellular domain. The intracellular domain is very short and has no known signaling motif. Furthermore, due to exon duplication, the human B7-H3 protein may contain one or two pairs of extracellular domains, thus forming two subtypes: 2IgB7-H3 and 4IgB7-H3. The former contains a pair of immunoglobulin variable region (IgV)-like and immunoglobulin constant region (IgC)-like extracellular domains, while the latter contains two identical pairs of IgV-like and IgC-like extracellular domains and is the predominant subtype found in human cells.

[0005] B7-H3 mRNA is widely expressed in normal tissues, while B7-H3 protein molecules are only expressed at low levels in a few tissues (Flem-Karlsen K. et al., (2018) Trends Cancer 4(6):401–404). For example, weak cytoplasmic staining is found in salivary gland acinar cells, gastric epithelial cells, and adrenal cells, and weak staining is found in the basal membrane of the stomach, gallbladder, prostate, cervix, and endometrium. B7-H3 protein is highly expressed in many malignant tumors. Multiple studies have shown that the expression rate of B7-H3 in renal cell carcinoma is 33.0% and in hepatocellular carcinoma is 91.8%. It is worth noting that the expression frequency of B7-H3 is lowest in renal cell carcinoma and hematological malignancies (33.0% and 36.7%, respectively, p<0.001), while the expression frequency of B7-H3 in all other solid cancer types is at least 52.3%. Among gastrointestinal tumors, hepatocellular carcinoma has the highest frequency of B7-H3 expression (91.8%), while gastric cancer has the lowest frequency (58.0%). Among genitourinary malignancies, renal cell carcinoma has the lowest frequency of B7-H3 expression, while ovarian cancer has the highest frequency (88.3%). When all cancers are included, the cumulative frequency of B7-H3 positivity is 59.5% (15,877 / 26,703). On the other hand, pancreatic cancer patients with high tumor B7-H3 expression have been found to have significantly better postoperative prognosis than those with low B7-H3 expression (Loos M. et al., (2009) BMC Cancer 9:463). On the other hand, it is believed that B7-H3 can establish an immunosuppressive immune microenvironment to help, for example, squamous cell carcinoma stem cells escape immune surveillance (Wang C. et al., (2021) Cell Stem Cell 28(9): 1597-1613; Jin MZ, Jin WL., (2020) Signal Transduct Target Ther 5(1): 166). Moreover, B7-H3 can also promote the occurrence and development of cancer through some non-immune pathways, such as inducing colorectal cancer cells to express VEGFA, promoting epithelial-mesenchymal transition in colorectal cancer, triggering aerobic glycolysis to provide energy for tumors, etc. (Wang RQ et al., (2020) Cell Death Dis (2020) 11(1): 55; Jiang B. et al., (2016) Oncotarget 7(22): 31755-31771; Lim S. et al., (2016) Cancer Res 76(8): 2231-2242).

[0006] The expression pattern of B7-H3 in vivo makes it a promising target for cancer therapy. In particular, B7-H3 is highly expressed on stromal fibroblasts and tumor-associated blood vessels (TAVs) within the tumor microenvironment, making it possible to eliminate cancer cells with low B7-H3 expression through B7-H3-targeted therapy.

[0007] Currently, multiple B7-H3-targeting drugs are in clinical development. Enoblituzumab is the first monoclonal antibody targeting the B7-H3 protein with Fc-optimized functionality. It achieves its anti-tumor effects through a dual mechanism of antibody-dependent cell-mediated cytotoxicity and enhanced T cell immune responses. In clinical studies, according to data presented at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting, enoximab combined with a PD-1 monoclonal antibody achieved an objective response rate (ORR) of 33.3% in patients with head and neck squamous cell carcinoma (SCCHN). The ORR also reached 35.7% in patients with non-small cell lung cancer (NSCLC) with low PD-L1 expression (<1%). In particular, patients who had previously received PD-1 / L1 antibody therapy not only responded to treatment again (partial response, PR), but also achieved disease control rates comparable to those seen in PD-1 / L1-naive patients. 131 The I-labeled monoclonal antibody 8H9 (Omburtamab, Y-mAbs) has been used in patients with metastatic central nervous system neuroblastoma (NCT00089245) and desmoplastic small round cell tumor (NCT01099644) for intraperitoneal injection and was well tolerated. Similarly, it was tested in diffuse pontine glioma (NCT01502917). 124 I-labeled monoclonal antibody 8H9 is also well tolerated. Other drugs targeting B7-H3, including small molecule drugs, monospecific antibodies, bispecific antibodies, antibody-drug conjugates, and CAR-T, are also in clinical trials for a variety of solid tumors such as melanoma, prostate cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, central nervous system tumors, glioblastoma, desmoplastic small round cell tumor, and medulloblastoma (Zhou WT, Jin WL. (2021) Front Immunol 12:701006).

[0008] However, despite the broad-spectrum tumor suppressive effects of B7-H3 targeted therapy, it is still in the early stages of clinical development and has only been shown to be effective in a small number of patients. Furthermore, it is important to note that some patients may initially respond very well to treatment but develop drug resistance over time. Identifying the causes of partial responses and drug resistance, and then developing new treatment modalities and approaches, is crucial for cancer treatment. There is still a huge demand for more B7-H3 antibodies with different properties and efficacy characteristics, such as those with different affinities, blocking activities, and even different binding epitopes, in the field of cancer treatment.

[0009] The citation of any document in this application does not constitute an admission that these documents are prior art to this application.

[0010] Summary of the Invention

[0011] The present application provides an isolated monoclonal antibody, for example, a human or chimeric monoclonal antibody that binds to B7-H3 (e.g., human B7-H3, monkey B7-H3, or mouse B7-H3). Compared to prior art antibodies such as enoxaparin, the monoclonal antibody has comparable or higher human / monkey B7-H3 binding affinity / activity, comparable or better B7-H3-positive cell binding, comparable or better immune cell activation ability such as NK cells, comparable or better antibody-dependent cell-mediated cytotoxicity (ADCC) induction, and comparable or better in vivo anti-tumor efficacy. The monoclonal antibody of the present application can also be internalized by B7-H3-positive cells and has stronger binding specificity to human B7-H3 than prior art antibodies such as enoxaparin.

[0012] The antibodies of the present application can be used in a variety of applications, including the treatment of B7-H3-related diseases such as cancer.

[0013] Thus, in one aspect, the present application relates to an isolated monoclonal antibody (e.g., a human antibody), or an antigen-binding portion thereof, that binds to B7-H3 and can contain i) a heavy chain variable region comprising a VH CDR1 region, a VH CDR2 region, and a VH CDR3 region, wherein the VH CDR1 region, the VH CDR2 region, and the VH CDR3 region can comprise, respectively, (1) SEQ ID NOs: 1, 2, and 3; (2) SEQ ID NOs: 1, 7, and 8; (3) SEQ ID NOs: 12, 13, and 14; (4) SEQ ID NOs: 18, 19, and 20; or (5) SEQ ID NOs: NOs:23, 24 and 25, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto; and / or ii) a light chain variable region comprising a VL CDR1 region, a VL CDR2 region and a VL CDR3 region, wherein the VL CDR1 region, the VL CDR2 region and the VL CDR3 region may comprise (1) SEQ ID NOs:4, 5 and 6; (2) SEQ ID NOs:9, 10 and 11; (3) SEQ ID NOs:15, 16 and 17; (4) SEQ ID NOs:9, 21 and 22; or (5) SEQ ID The amino acid sequences shown in NOs:26, 27 and 28, or amino acid sequences that are at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the above sequences.

[0014] The isolated monoclonal antibody or antigen-binding portion thereof of the present application can comprise a heavy chain variable region and a light chain variable region, wherein the VH CDR1 region, VH CDR2 region, VH CDR3 region, VL CDR1 region, VL CDR2 region and VL CDR3 region can respectively comprise (1) SEQ ID NOs: 1, 2, 3, 4, 5 and 6; (2) SEQ ID NOs: 1, 7, 8, 9, 10 and 11; (3) SEQ ID NOs: 12, 13, 14, 15, 16 and 17; (4) SEQ ID NOs: 18, 19, 20, 9, 21 and 22; or (5) SEQ ID NOs: 1 The amino acid sequences shown in NOs:23, 24, 25, 26, 27 and 28, or amino acid sequences that are at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the above sequences.

[0015] The heavy chain variable region of the isolated monoclonal antibody or antigen-binding portion thereof of the present application can comprise an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NOs: 29, 31, 33, 35 or 37.

[0016] The light chain variable region of the isolated monoclonal antibody or antigen-binding portion thereof of the present application can comprise an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NOs: 30, 32, 34, 36 or 38.

[0017] The heavy chain variable region and light chain variable region of the isolated monoclonal antibody or antigen-binding portion thereof of the present application can respectively comprise the amino acid sequences shown in (1) SEQ ID NOs: 29 and 30; (2) SEQ ID NOs: 31 and 32; (3) SEQ ID NOs: 33 and 34; (4) SEQ ID NOs: 35 and 36; or (5) SEQ ID NOs: 37 and 38; or amino acid sequences having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto.

[0018] In another aspect, the present application relates to an isolated monoclonal antibody (e.g., a human antibody), or an antigen-binding portion thereof, that binds to B7-H3, comprising i) a heavy chain variable region comprising a VH CDR1 region, a VH CDR2 region, and a VH CDR3 region, wherein the VH CDR1 region, the VH CDR2 region, and the VH CDR3 region are identical to the VH CDR1 region, the VH CDR2 region, and the VH CDR3 region of a selected VH sequence, respectively, and / or ii) a light chain variable region comprising a VL CDR1 region, a VL CDR2 region, and a VL CDR3 region, wherein the VL CDR1 region, the VL CDR2 region, and the VL CDR3 region are identical to the VL CDR1 region, the VL CDR2 region, and the VL CDR3 region of a selected VL sequence, respectively. The CDR3 region has identity; wherein the selected VH sequence and the selected VL sequence are one of the following: (1) the selected VH sequence and the selected VL sequence are SEQ ID NOs: 29 and 30, respectively; (2) the selected VH sequence and the selected VL sequence are SEQ ID NOs: 31 and 32, respectively; (3) the selected VH sequence and the selected VL sequence are SEQ ID NOs: 33 and 34, respectively; (4) the selected VH sequence and the selected VL sequence are SEQ ID NOs: 35 and 36, respectively; (5) the selected VH sequence and the selected VL sequence are SEQ ID NOs: 37 and 38, respectively.

[0019] In one embodiment, the isolated monoclonal antibody or its antigen-binding portion of the present application may comprise a heavy chain constant region and / or a light chain constant region. The heavy chain constant region may be an IgG1, IgG2, IgG3, or IgG4 heavy chain constant region, or a functional fragment thereof. Furthermore, the heavy chain constant region may be engineered, for example, to have enhanced FcR binding to enhance ADCC activity against B7-H3-positive cells. For example, the heavy chain constant region may introduce an S1 mutation (EU numbering: S239D and I332E mutations) or a VLPLL mutation (EU numbering: L235V, F243L, R292P, Y300L, and P396L). In one embodiment, the heavy chain variable region may be a wild-type human IgG1 constant region having the amino acid sequence of SEQ ID NO: 43. In one embodiment, the heavy chain variable region may be a human IgG1 constant region having the amino acid sequence of SEQ ID NO: 44 (EU numbering: L235V, F243L, R292P, Y300L, and P396L). The light chain constant region may be a kappa constant region, such as a human kappa constant region having the amino acid sequence of SEQ ID NO: 45 or a functional fragment thereof, wherein the N-terminus of the heavy chain constant region is connected to the C-terminus of the heavy chain variable region, and the N-terminus of the light chain constant region is connected to the C-terminus of the light chain variable region.

[0020] The antibodies or antigen-binding portions thereof of the present application can be recombinantly expressed, for example, in certain mammalian cell lines for defucosylation. Cell lines that can express defucosylated antibodies or antigen-binding portions thereof include, but are not limited to, Slc35C1 gene knockout cell lines, FUT8 knockout cell lines, variant CHO cell lines Lec13, rat hybridoma cell lines YB2 / 0, cell lines containing small interfering RNA specifically against the FUT8 gene, and cell lines that co-express β-1,4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II.

[0021] The antibodies of the present application, in some embodiments, comprise two heavy chains and two light chains, or are composed of two heavy chains and two light chains, wherein each heavy chain comprises the aforementioned heavy chain constant region sequence, heavy chain variable region sequence and / or CDR sequence, and each light chain comprises the aforementioned light chain constant region sequence, light chain variable region sequence and / or CDR sequence. In some embodiments, the antibodies of the present application may be single-chain antibodies, or be composed of antibody fragments, such as Fab or F(ab')2 fragments.

[0022] The application also provides an immunoconjugate containing the present application antibody or its antigen-binding portion thereof, and the antibody or its antigen-binding portion thereof is connected to a therapeutic agent such as a cytotoxin or an anticancer agent. The application also provides a bispecific molecule containing the present application antibody or its antigen-binding portion thereof, the antibody or its antigen-binding portion thereof is connected with a second functional group, for example, a second antibody, and the second functional group has a binding specificity different from the present application antibody or its binding portion thereof. On the other hand, the present application's antibody or its antigen-binding portion thereof can be a part of a chimeric antigen receptor (CAR) or a genetically modified T cell receptor (TCR). The application also provides immune cells containing the above-mentioned CAR and / or TCR, including T cells, NK cells, etc. The antibody or its antigen-binding portion thereof of the present invention can also be encoded by an oncolytic virus or carried by an oncolytic virus.

[0023] The present application also includes nucleic acid molecules encoding the antibodies or antigen-binding portions thereof, or bispecific molecules of the present application, as well as expression vectors comprising the nucleic acids and host cells comprising the expression vectors.

[0024] In one embodiment, the expression vector of the present application comprises one or more of the above-mentioned nucleic acids. In another embodiment, the expression vector of the present application comprises two of the above-mentioned nucleic acids, each encoding a VH and a VL that can jointly bind to B7-H3. In another embodiment, the present application relates to a pair of vectors, wherein each vector comprises one of the above-mentioned nucleic acids, and the paired vectors jointly encode a VH and a VL that can bind to B7-H3.

[0025] The present application also provides a method for preparing the antibody, or antigen-binding portion thereof, or bispecific molecule of the present application using a host cell containing the above-mentioned expression vector, comprising: (i) expressing the antibody, its antigen-binding portion, or bispecific molecule in the host cell, and (ii) isolating the antibody, its antigen-binding portion, or bispecific molecule from the host cell or its culture.

[0026] The present application also provides a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, immunoconjugate, bispecific molecule, immune cell, oncolytic virus, nucleic acid molecule, expression vector or host cell of the present application, and a pharmaceutically acceptable carrier.

[0027] In one aspect, the present application provides a method for treating or slowing down a B7-H3 related disease in a subject, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of the present application. B7-H3 related diseases can be cancer or autoimmune diseases. Cancer can be a solid tumor, including but not limited to breast cancer, melanoma, prostate cancer, head and neck squamous cell carcinoma, lung cancer, non-small cell lung cancer, central nervous system neuroblastoma, glioblastoma, desmoplastic small round cell tumor, diffuse pontine glioma, medulloblastoma, pancreatic cancer, liver cancer, colorectal cancer, non-Hodgkin's lymphoma, esophageal cancer, ovarian cancer, bladder cancer, small cell carcinoma, endometrial cancer, renal cancer, gastric cancer, acute myeloid leukemia, hepatocellular carcinoma, hypopharyngeal squamous cell carcinoma, urothelial cell carcinoma. Autoimmune diseases include but are not limited to asthma. In some embodiments, the present application antibody or its antigen-binding portion can be administered together with at least one other anti-cancer antibody, such as PD-1 antibody, PD-L1 antibody, 4-1BB antibody, etc. In another embodiment, the antibody of the present application or its antigen binding portion thereof is administered together with a cytokine (e.g., IL-2 and / or IL-21) or a co-stimulatory antibody (e.g., CD137 antibody and / or GITR antibody). In another embodiment, the antibody of the present application or its antigen binding portion thereof can be administered together with a chemotherapeutic agent, which can be a cytotoxic agent. The antibody of the present application can be, for example, a human antibody.

[0028] In one aspect, the present application provides a method for enhancing an immune response in a subject, comprising administering an effective amount of an antibody or antigen-binding portion thereof to a subject in need thereof. Enhancing the immune response includes activating immune cells, including NK cells, and the like.

[0029] All documents cited or mentioned in this application (including but not limited to all documents, patents, published patent applications cited herein) ("this application's references"), all documents cited or mentioned in this application's references, and manufacturer's manuals, instructions, product specifications, and product pages for any product mentioned in this application or any of this application's references are incorporated herein by reference and may be used in practicing the present invention. More specifically, all references are incorporated herein by reference, just as each file is incorporated by reference. Any Genbank sequence mentioned in this article is incorporated herein by reference.

[0030] It should be noted that in this application, especially in the claims, terms such as "comprising" and "including" may have the meanings assigned to them by the Chinese Patent Law; and terms such as "essentially consisting of..." have the meanings assigned to them by the Chinese Patent Law, such as allowing the existence of elements not explicitly stated, but excluding elements existing in the prior art or elements that affect the basic or new characteristics of the invention.

[0031] Based on the following specific description and examples, other features and advantages of the current disclosure will become clearer, and specific description and examples should not be interpreted as restrictive. The contents of all documents, Genbank records, patents and published patent applications cited in this application are expressly included in this article by reference. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] The following detailed description is given by way of example but is not intended to limit the present invention to the specific embodiments described, and can be better understood in conjunction with the accompanying drawings.

[0033] FIG1 shows the binding activity of fully human B7-H3 antibodies to B7-H3-positive tumor cells, including A549 cells (A), NCI-H520 cells (B), HepG2 cells (C), SK-OV-3 cells (D), and MCF-7 cells (E).

[0034] FIG2 shows the binding activity of fully human B7-H3 antibodies to B7-H3-negative tumor cells, including Jurkat cells (A), Daudi cells (B), and Raji cells (C).

[0035] FIG3 shows the binding activity of fully human B7-H3 antibodies to B7-H3-positive normal cells, including human prostate smooth muscle cells (A), human dermal fibroblasts (B), human aortic smooth muscle cells (C), and human dendritic cells (D).

[0036] Figure 4 shows the binding activity of fully human B7-H3 antibodies 6B5-WT, 6B5-AF, and 6B5-Mut before and after Fc modification to HUVEC cells (A) and NCI-H520 cells (C), as well as the binding activity of 10D7-WT, 10D7-AF, and 10D7-Mut to HUVEC cells (B) and NCI-H520 cells (D).

[0037] Figure 5 shows the ability of fully human B7-H3 antibodies 10D7-WT, 10D7-AF and 10D7-Mut before and after Fc modification to trigger NK cells to kill NCI-H520 cells (A) and activate NK cells (C), as well as the ability of 6B5-WT, 6B5-AF and 6B5-Mut to trigger NK cells to kill NCI-H520 cells (B) and activate NK cells (D).

[0038] Figure 6 shows the ability of fully human B7-H3 antibodies 10D7-WT, 10D7-AF and 10D7-Mut before and after Fc modification to induce PBMC cells to kill NCI-H520 cells (A), and the ability of 6B5-WT, 6B5-AF and 6B5-Mut to induce PBMC cells to kill NCI-H520 cells (B).

[0039] Figure 7 shows the ability of defucosylated fully human B7-H3 antibodies 10D7-AF and 6B5-AF to trigger NK cells (A) or PBMC (B) to kill HUVEC cells (A), and the amount of IFN-γ secreted during the killing of HUVEC cells by PBMC cells (C).

[0040] FIG8 shows the ability of defucosylated fully human B7-H3 antibodies 10D7-AF and 6B5-AF to trigger NK cell killing of mature dendritic cells.

[0041] FIG9 shows the endocytic effect of fully human B7-H3 antibodies in NCI-H520 cells (A) and A549 cells (B).

[0042] FIG10 shows a dendrogram of the B7-H3 binding epitopes of fully human B7-H3 antibodies calculated using the average linkage clustering method.

[0043] FIG11 shows the binding of the 6B5 antibody to B7 family members detected by SPR.

[0044] FIG12 shows the changes in tumor volume in humanized B7-H3 mice treated with fully human B7-H3 antibodies 10F5-Mut (A), 6B5-Mut, and 15F11-Mut (B).

[0045] FIG13 shows representative tissue staining results of the defucosylated fully human B7-H3 antibody 6B5-AF. DETAILED DESCRIPTION

[0046] For a better understanding of this application, some terms are first defined. Other definitions are listed throughout the detailed description.

[0047] The term "B7-H3" refers to B7 analog 3, also known as cluster of differentiation 276 (CD276). It can be divided into two subtypes, namely 4Ig type and 2Ig type, based on the difference in the extracellular domain structure. The term includes variants, homologs, orthologs, and paralogs. For example, an antibody specific for human B7-H3 may, in some cases, cross-react with B7-H3 proteins from another species, such as monkeys. In other embodiments, an antibody specific for human B7-H3 protein may be completely specific for human B7-H3 protein and not cross-react with proteins from other species or other types, or may cross-react with B7-H3 proteins from some other species but not all other species.

[0048] The term "human B7-H3" refers to a B7-H3 protein having a human amino acid sequence, such as the B7-H3 (4Ig) protein having an amino acid sequence with NCBI accession number NP_001019907.1 (Kanayama T. et al., (2021) Sci Rep 11(1):18802), or the B7-H3 (2Ig) protein having an amino acid sequence with NCBI accession number NP_001316557.1 (Fu M. et al., (2021) J Transl Med 19(1):404). The term "monkey B7-H3" refers to a B7-H3 protein having a monkey amino acid sequence, such as the B7-H3 protein having an amino acid sequence with NCBI accession number XP_015308534.1. The term "mouse B7-H3" refers to a B7-H3 protein having mouse amino acid sequence, such as a B7-H3 protein having an amino acid sequence with NCBI index number NP_598744.1 (Cheng N. et al., (2021) Biochem Pharmacol 183: 114298).

[0049] The term "antibody" as used herein is intended to include IgG, IgA, IgD, IgE and IgM full-length antibodies and any antigen-binding fragments (i.e., antigen-binding portions) thereof. A full-length antibody is a glycoprotein comprising at least two heavy (H) chains and two light (L) chains connected by disulfide bonds. Each heavy chain consists of a heavy chain variable region (V H The heavy chain constant region is composed of three domains, namely C H1 、C H2 and C H3 Each light chain consists of a light chain variable region (V L or VL) and the light chain constant region. The light chain constant region consists of a domain C L Composition. H and V LThe V domains can be further divided into regions of hypervariability, termed complementarity determining regions (CDRs), separated by more conserved framework regions (FRs). H and V L It is composed of three CDRs and four FRs, arranged in the order of FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 from the amino terminus to the carboxyl terminus. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of an antibody can mediate the binding of immunoglobulins to host tissues or factors, including binding to a variety of immune system cells (e.g., effector cells) and the first component (C1q) of the traditional complement system. A "functional fragment" of an antibody constant region refers to a fragment that retains certain desired functions in the constant region, such as a fragment that retains FcR / complement system component binding activity in the heavy chain constant region.

[0050] The term "antigen-binding portion" of an antibody (or simply "antibody portion") as used herein refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., B7-H3 protein). It has been demonstrated that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments included in the "antigen-binding portion" of an antibody include (i) a Fab fragment, which is comprised of a V L 、V H 、C L and C H1 (ii) F(ab')2 fragment, a bivalent fragment comprising two Fab fragments connected by a disulfide bridge in the hinge region; (iii) V H and C H1 (iv) an Fd fragment consisting of an antibody single-arm V L and V H Fv fragment composed of V H (vi) a single variable domain and two constant domains; and (vii) a nanobody, a heavy chain variable region comprising a single variable domain and two constant domains. L and V H Encoded by different genes, they can be recombinantly linked via a synthetic linker that makes the two into a single protein chain, where V L and V HThe antibody fragments are formed by pairing the antibody domains to form monovalent molecules (called single-chain Fc (scFv); see, for example, Bird et al., (1988) Science 242:423-426; and Huston et al., (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). These single-chain antibodies are also intended to be included in the meaning of the term. These antibody fragments can be obtained by common techniques known to those skilled in the art, and the fragments can be screened for function in the same manner as intact antibodies.

[0051] As used herein, the term "isolated antibody" refers to an antibody that is substantially free of other antibodies with different antigenic specificities. For example, an isolated antibody that specifically binds to a B7-H3 protein is substantially free of antibodies that specifically bind to antigens other than the B7-H3 protein. However, an isolated antibody that specifically binds to a human B7-H3 protein may have cross-binding properties to other antigens, such as B7-H3 proteins from other species. Furthermore, an isolated antibody is substantially free of other cellular material and / or chemicals.

[0052] The term "monoclonal antibody" or "mAb" or "monoclonal antibody composition" refers to an antibody molecule preparation of a single molecular composition. A monoclonal antibody composition exhibits a single binding specificity and affinity for a particular epitope.

[0053] The term "human antibody" refers to an antibody whose variable region framework and CDR region are derived from human germline immunoglobulin sequences. In addition, if the antibody contains a constant region, it is also derived from human germline immunoglobulin sequences. The human antibodies of the present application may contain amino acid residues that are not encoded by human germline immunoglobulin sequences, such as mutations introduced by random mutations or point mutations in vitro or by somatic mutations in vivo. However, the term "human antibody" does not include antibodies in which CDR sequences derived from other mammalian species are inserted into human framework sequences.

[0054] The term "chimeric antibody" refers to an antibody that is derived from a combination of non-human genetic material and human genetic material. More generally, a chimeric antibody is one that combines genetic material from one species with that from another.

[0055] The terms "antibody that recognizes an antigen" and "antibody specific for an antigen" are used interchangeably herein with the term "antibody that specifically binds to an antigen."

[0056] In this article, an antibody that "specifically binds to human B7-H3" refers to an antibody that binds to human B7-H3 (and B7-H3 from other non-human species) but does not substantially bind to non-B7-H3 proteins. Preferably, the antibody binds to human B7-H3 protein with "high affinity", i.e., K D The value is 5.0x10 -8 Below M.

[0057] The term "substantially not binding" to a protein or cell means that the protein or cell does not bind to the protein or cell, or does not bind to the protein or cell with high affinity, i.e., the K of the protein or cell is less than 1%. D 1.0x10 -6 M or more, more preferably 1.0x10 -5 M or more, more preferably 1.0x10 -4 M or above, 1.0x10 -3 M or more, more preferably 1.0x10 -2 M or above.

[0058] The term "EC 50 ", also known as half-maximal effect concentration, refers to the antibody concentration that causes 50% of the maximum effect.

[0059] The term "IC 50 ” refers to the half-inhibitory concentration, which is the concentration of the drug or inhibitor required to inhibit a specified biological process by half.

[0060] The terms "antibody-dependent cellular cytotoxicity," "antibody-dependent cell-mediated cytotoxicity," or "ADCC" refer to a cell-mediated immune defense in which immune system effector cells actively lyse target cells that have cell membrane surface antigens bound to antibodies, such as the B7-H3 antibodies of the present application.

[0061] The term "subject" includes any human or non-human animal. The term "non-human animal" includes all vertebrates, such as mammals and non-mammals, such as non-human primates, sheep, dogs, cats, cows, horses, chickens, amphibians, and reptiles, although mammals, such as non-human primates, sheep, dogs, cats, cows and horses, are preferred.

[0062] The term "therapeutically effective amount" refers to an amount of the antibody of the present invention sufficient to prevent or alleviate the symptoms associated with a disease or disorder (e.g., cancer). The therapeutically effective amount is related to the disease being treated, and those skilled in the art can easily determine the actual effective amount.

[0063] Various aspects of the application are described in more detail below.

[0064] The antibodies or antigen-binding portions thereof of the present application can specifically bind to B7-H3 of humans, monkeys, etc., including B7-H3-positive cells, and the binding activity / binding affinity is comparable to or better than that of prior art antibodies such as Enoxolone. In addition, compared with prior art antibodies such as Enoxolone, the antibodies or antigen-binding portions thereof of the present application have comparable or better immune cell activation ability such as NK cells, comparable or better antibody-dependent cell-mediated cytotoxicity (ADCC) guidance effect, and comparable or better in vivo anti-tumor effect. The monoclonal antibodies or antigen-binding portions thereof of the present application can also be endocytosed by B7-H3-positive cells, and have stronger binding specificity to human B7-H3 than prior art antibodies such as Enoxolone.

[0065] The preferred antibodies of the present application are monoclonal antibodies. In addition, the antibodies can be, for example, human or chimeric monoclonal antibodies.

[0066] Exemplary antibodies of the present application, or antigen-binding portions thereof, are those whose structural and chemical properties are described below.

[0067] The heavy chain variable region CDRs and light chain variable region CDRs of the antibodies or antigen-binding portions thereof of the present application are identified using the Kabat numbering system, and the SEQ ID NOs of the CDR region amino acid sequences are listed in Table 1A, along with the SEQ ID NOs of the heavy and light chain amino acid sequences. The heavy chain variable region CDRs and light chain variable region CDRs of the antibodies or antigen-binding portions thereof of the present application can also be identified using the Chothia numbering system, and the SEQ ID NOs of the CDR region amino acid sequences identified using this system are listed in Table 1B.

[0068] Table 1A. Heavy chain / light chain variable region CDRs and amino acid sequences of heavy chain / light chain variable regions determined by the Kabat numbering system SEQ ID NO.

[0069]

[0070] Table 1B. Chothia numbering system determined heavy chain / light chain variable region CDR and heavy chain / light chain variable region amino acid sequence SEQ ID NO.

[0071]

[0072] In addition to the CDR regions whose sequences are determined by the Kabat and Chothia numbering systems exemplified above, the heavy and light chain variable region sequences of the antibodies of the present application may also have CDR regions determined by other coding methods based on the sequences of SEQ ID NOs: 29, 30, 31, 32, 33, 34, 35, 36, 37, and 38. It is well known in the art that the heavy and light chain variable region CDRs may also be determined by numbering systems / methods such as IMGT, AbM, or Contact.

[0073] The antibodies of the present application may have a heavy chain constant region, for example, an IgG1 constant region, such as a human IgG1 constant region comprising the amino acid sequence set forth in SEQ ID NO: 43. The constant region may be engineered to have enhanced FcR binding, such as a human IgG1 constant region comprising the amino acid sequence set forth in SEQ ID NO: 44 (EU numbering: L235V, F243L, R292P, Y300L, and P396L). The light chain constant region may be a kappa constant region, such as a human kappa constant region, which may comprise the amino acid sequence set forth in SEQ ID NO: 45.

[0074] V of other B7-H3 antibodies that bind to human B7-H3 H and / or V L The sequence (or CDR sequence) can be the same as the V H and / or V L Sequences (or CDR sequences) are "mixed and paired". Preferably, when V H and V L When (or CDRs therein) are mixed and paired, a specific V H / V L V in pairing H The sequence can be approximated by the structure of V H Similarly, specific V H / V L V in pairing L The sequence is composed of structurally similar V L Sequence substitution.

[0075] Therefore, in one embodiment, the antibody or antigen-binding portion thereof of the present application comprises:

[0076] (a) a heavy chain variable region comprising the amino acid sequence listed in Table 1; and

[0077] (b) a light chain variable region comprising the amino acid sequence listed in Table 1, or a V region of another B7-H3 antibody L , wherein the antibody specifically binds to human B7-H3.

[0078] In another embodiment, the antibody or antigen-binding portion thereof of the present application comprises:

[0079] (a) CDR1, CDR2, and CDR3 of the heavy chain variable region listed in Table 1; and

[0080] (b) CDR1, CDR2, and CDR3 of the light chain variable region listed in Table 1, or the CDRs of another B7-H3 antibody, wherein the antibody specifically binds to human B7-H3.

[0081] In another embodiment, the antibody of the present application or its antigen-binding portion includes the heavy chain variable region CDR2 of the B7-H3 antibody and the CDRs of other antibodies that bind to human B7-H3, such as the heavy chain variable region CDR1 and / or CDR3, and / or the light chain variable region CDR1, CDR2 and / or CDR3 of another B7-H3 antibody.

[0082] Furthermore, it is well known in the art that the CDR3 domain, independent of CDR1 and / or CDR2, can independently determine the binding specificity of an antibody to the same antigen, and it can be predicted that multiple antibodies with the same binding specificity can be generated based on the CDR3 sequence. See, eg, Klimka et al., British J. of Cancer 83(2):252-260 (2000); Beiboer et al., J. Mol. Biol. 296:833-849 (2000); Rader et al., Proc. Natl. Acad. Sci. USA 95:8910-8915 (1998); Barbas et al. al., J.Am.Chem.Soc.116:2161-2162(1994); Barbas et al., Proc.Natl.Acad.Sci.USA92:2529-2533(1995); Ditzel et al., J.Immunol.157:739-749(1996); Berezov et al., BIAjournal 8:Scientific Review 8 (2001); Igarashi et al., J. Biochem (Tokyo) 117:452-7 (1995); Bourgeois et al., J. Virol 72:807-10 (1998); Levi et al., Proc.Natl.Acad.Sci.USA90:4374-8 (1993); Polymenis and Stoller,J.Immunol.152:5218-5329(1994)and Xu and Davis,Immunity 13:37-45 (2000); US Pat. Nos. 6,951,646; 6,914,128; 6,090,382; 6,818,216; 6,156,313; 6,827,925; 5,833,943; 5,762,905 and 5,760,185. These references are all incorporated herein by reference in their entirety.

[0083] In another embodiment, the antibody of the present application comprises the CDR2 of the heavy chain variable region of the B7-H3 antibody and at least the CDR3 of the heavy chain and / or light chain variable region of the B7-H3 antibody, or the CDR3 of the heavy chain and / or light chain variable region of another B7-H3 antibody, wherein the antibody is capable of specifically binding to human B7-H3. Preferably, these antibodies (a) compete for binding to B7-H3; (b) retain functional properties; (c) bind to the same epitope; and / or (d) have similar binding affinity as the B7-H3 antibody of the present application. In another embodiment, the antibody may further comprise the CDR2 of the light chain variable region of the B7-H3 antibody, or the CDR2 of the light chain variable region of another B7-H3 antibody, wherein the antibody specifically binds to human B7-H3. In another embodiment, the antibody of the present application may include the heavy chain / light chain variable region CDR1 of a B7-H3 antibody, or the heavy chain and / or light chain variable region CDR1 of another B7-H3 antibody, wherein the antibody specifically binds to human B7-H3.

[0084] In another embodiment, the antibody of the present application comprises a heavy chain and / or light chain variable region sequence or CDR1, CDR2 and CDR3 sequence that has one or more conservative modifications compared to the B7-H3 antibody of the present application. It is known in the art that some conservative sequence modifications do not abolish antigen binding. See, for example, Brummell et al., (1993) Biochem 32:1180-8; de Wildt et al., (1997) Prot. Eng. 10:835-41; Komissarov et al., (1997) J. Biol. Chem. 272:26864-26870; Hall et al. al., (1992) J.Immunol.149:1605-12; Kelley and O'Connell (1993) Biochem.32:6862-35; Adib-Conquy et al., (1998) Int.Immunol.10:341-6 and Beers et al. al., (2000) Clin. Can. Res. 6:2835-43.

[0085] Thus, in one embodiment, the antibody comprises a heavy chain variable region and / or a light chain variable region, the heavy chain variable region and the light chain variable region comprising CDR1, CDR2 and CDR3, respectively, wherein:

[0086] (a) the heavy chain variable region CDR1 comprises the sequence listed in Table 1, and / or conservative modifications thereof; and / or

[0087] (b) the heavy chain variable region CDR2 comprises the sequence listed in Table 1, and / or conservative modifications thereof; and / or

[0088] (c) the heavy chain variable region CDR3 comprises the sequence listed in Table 1, and / or conservative modifications thereof; and / or

[0089] (d) the light chain variable region CDR1, and / or CDR2, and / or CDR3 comprise the sequences listed in Table 1, and / or conservative modifications thereof; and

[0090] (e) The antibody specifically binds to human B7-H3.

[0091] The antibodies of the present application have one or more of the following functional characteristics, such as high affinity and high specific binding to human B7-H3, as well as enhanced FcR binding, and correspondingly enhanced ability to induce ADCC on B7-H3-positive tumor cells.

[0092] In various embodiments, the antibody or antigen-binding portion thereof can be, for example, human or chimeric.

[0093] The term "conservative sequence modification" as used herein refers to an amino acid modification that does not significantly affect or change the binding properties of an antibody. Such conservative modifications include amino acid replacements, additions, and deletions. Modifications can be introduced into the present application's antibodies by standard techniques known in the art, such as point mutations and PCR-mediated mutations. Conservative amino acid replacements are amino acid residues that are replaced with amino acid residues with similar side chains. Groups of amino acid residues with similar side chains are known in the art. These groups of amino acid residues include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), β-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues in the CDR region of the antibody of the present application can be replaced with other amino acid residues from the same side chain group, and the resulting antibody can be tested for retention of function (i.e., the function described above) using the functional assays described herein.

[0094] The antibody of the present application can be prepared by using one or more V H / V L The antibody sequence is used as the starting material to prepare the genetically modified antibody. The antibody can be prepared by modifying one or two variable regions (i.e., V H and / or V L) (e.g., in one or more CDR regions and / or one or more framework regions) to improve binding affinity and / or increase similarity to antibodies naturally produced by certain species. Alternatively, antibodies can be genetically modified by modifying residues in the constant region, for example, to alter the effector function of the antibody.

[0095] In certain embodiments, CDR regions are implanted into the variable regions of genetically modified antibodies. Antibodies interact with target antigens primarily through amino acid residues located in the six heavy and light chain complementary determining regions (CDRs). For this reason, the amino acid residues within the CDRs are more diverse between individual antibodies than the sequences outside the CDRs. Because CDR sequences are responsible for the primary antibody-antigen interaction, recombinant antibodies that mimic the properties of a specific natural antibody can be expressed by constructing an expression vector containing the CDR sequence of a specific natural antibody implanted into the framework sequence of a different antibody with different properties (Riechmann et al., (1998) Nature 332:323-327; Jones et al., (1986) Nature 321:522-525; Queen et al., (1989) Proc. Natl. Acad; USA 86:10029-10033; US Pat. Nos. 5,225,539; 5,530,101; 5,585,089; 5,693,762 and 6,180,370).

[0096] Therefore, another embodiment of the present application relates to an isolated monoclonal antibody or antigen-binding portion thereof, which comprises a heavy chain variable region and / or a light chain variable region, wherein the heavy chain variable region comprises CDR1, CDR2 and CDR3 having the above-mentioned sequence of the present application, and the light chain variable region comprises CDR1, CDR2 and CDR3 having the above-mentioned sequence of the present application. Although these antibodies comprise the V H and V L CDR sequences, which may contain different framework sequences.

[0097] Such framework sequences can be obtained from public DNA databases or published references that include germline antibody gene sequences. For example, germline DNA sequences for human heavy and light chain variable region genes can be found in the Vbase human germline sequence database (www.mrc-cpe.cam.ac.uk / vbase) and in Kabat et al., (1991), supra; Tomlinson et al., (1992) J. Mol. Biol. 227:776-798; and Cox et al., (1994) Eur. J. Immunol. 24:827-836. As another embodiment, germline DNA sequences for human heavy and light chain variable region genes can be found in the Genbank database. For example, the Genbank accession numbers for the heavy chain germline sequences in the following HCo7 HuMAb mouse are 1-69 (NG-0010109, NT-024637 & BC070333), 3-33 (NG-0010109 & NT-024637), and 3-7 (NG-0010109 & NT-024637). As another example, the following heavy chain germline sequences from the Hco12 HuMAb mouse have Genbank accession numbers 1-69 (NG--0010109, NT--024637 & BC070333), 5-51 (NG--0010109 & NT--024637), 4-34 (NG--0010109 & NT--024637), 3-30.3 (CAJ556644), and 3-23 (AJ406678).

[0098] The antibody protein sequence is compared to protein sequence databases by using one of the sequence similarity search methods known in the art as gapped BLAST (Altschul et al., (1997)).

[0099] Preferred framework sequences for use in the antibodies of the present application are those that are structurally similar to the framework sequences used in the antibodies of the present application. H The CDR1, CDR2, and CDR3 sequences can be implanted into a framework region having the same sequence as the germline immunoglobulin gene from which the framework sequence is derived, or the CDR sequences can be implanted into a framework region that contains one or more mutations compared to the germline sequence. For example, in some cases, it is beneficial to mutate residues in the framework region to maintain or enhance the antigen binding of the antibody (see, e.g., U.S. Pat. Nos. 5,530,101; 5,585,089; 5,693,762 and 6,180,370).

[0100] Another type of variable region modification is to modify V Hand / or V L The amino acid residues in the CDR1, CDR2 and / or CDR3 regions are mutated to improve one or more binding properties (e.g., affinity) of the target antibody. Point mutations or PCR-mediated mutations can be performed to introduce mutations, and their effects on antibody binding or other functional properties can be evaluated in in vitro or in vivo assays known in the art. Preferably, conservative modifications known in the art are introduced. The mutations can be amino acid replacements, additions, or deletions, but are preferably replacements. In addition, no more than one, two, three, four, or five residues in the CDR regions are typically changed.

[0101] In another embodiment, the present application provides an isolated B7-H3 monoclonal antibody or an antigen-binding portion thereof, comprising a heavy chain variable region and a light chain variable region, which comprises: (a) V H CDR1 region, comprising the sequence of the present application, or an amino acid sequence with one, two, three, four or five amino acid substitutions, deletions or additions; (b) V H CDR2 region, comprising the sequence of the present application, or an amino acid sequence with one, two, three, four or five amino acid substitutions, deletions or additions; (c) V H CDR3 region, comprising the sequence of the present application, or an amino acid sequence with one, two, three, four or five amino acids substituted, deleted or added; (d) V L CDR1 region, comprising the sequence of the present application, or an amino acid sequence with one, two, three, four or five amino acids substituted, deleted or added; (e) V L CDR2 region, comprising the sequence of the present application, or an amino acid sequence with one, two, three, four or five amino acid substitutions, deletions or additions; and (f) V L The CDR3 region comprises the sequence of the present application, or an amino acid sequence with one, two, three, four or five amino acids substituted, deleted or added.

[0102] The genetically modified antibodies of the present application are included in V H and / or V L Genetic modifications are made to the framework residues of the antibody to, for example, alter the properties of the antibody. Framework modifications include mutating one or more residues in the framework region, or even one or more CDR regions, to remove T cell epitopes, thereby reducing the potential immunogenicity of the antibody. This approach, also known as "deimmunization," is described in more detail in U.S. Patent Publication No. 20030153043.

[0103] In addition, as an alternative to modifications within the framework or CDR regions, the antibodies of the present application can be genetically engineered to include genetic modifications in the Fc region, generally to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding, and / or antibody-dependent cellular cytotoxicity. In addition, the antibodies of the present application can be chemically modified (e.g., one or more chemical functional groups can be added to the antibody), or modified to alter its glycosylation to alter one or more functional properties of the antibody.

[0104] In one embodiment, C H1 The hinge region of the hinge region is modified to change, for example, increase or decrease the number of cysteine ​​residues in the hinge region. This method is further described in U.S. Patent No. 5,677,425. H1 The cysteine ​​residues in the hinge region can be used to, for example, facilitate the assembly of the heavy and light chains or to increase / decrease the stability of the antibody.

[0105] In another embodiment, the Fc hinge region of the antibody is mutated to increase or decrease the biological half-life of the antibody. More specifically, one or more amino acid mutations are introduced into the C H2 -C H3 The linker region is then used to create an antibody that has reduced SpA binding relative to the native Fc-hinge domain SpA binding. This approach is described in more detail in US Patent No. 6,165,745.

[0106] In another embodiment, the glycosylation of the antibody is modified. For example, a deglycosylated antibody (i.e., the antibody lacks glycosylation) can be prepared. Glycosylation can be altered to, for example, increase the affinity of the antibody for the antigen. Such glycosylation modification can be achieved by, for example, altering one or more glycosylation sites in the antibody sequence. For example, one or more amino acid substitutions can be made to eliminate one or more variable region backbone glycosylation sites, thereby eliminating glycosylation at that position. Such deglycosylation can increase the affinity of the antibody for the antigen. See, for example, U.S. Patents 5,714,350 and 6,350,861.

[0107] In addition, antibodies with altered glycosylation patterns can be prepared, such as hypofucosyl antibodies with reduced amounts of fucose residues, or antibodies with increased bisecting GlcNac structures. Altered glycosylation patterns have been shown to increase the ADCC activity of antibodies. Such glycosylation modifications can be performed, for example, by expressing the antibody in a host cell with an altered glycosylation system. Cells with altered glycosylation systems are known in the art and include, but are not limited to, Slc35c1 gene knockout cell lines, FUT8 knockout cell lines, variant CHO cell lines Lec13, rat hybridoma cell lines YB2 / 0, cell lines containing small interfering RNA specifically targeting the FUT8 gene, and cell lines that co-express β-1,4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II. These can be used as host cells for expressing the recombinant antibodies of the present application to prepare antibodies with altered glycosylation. The Slc35c1 gene knockout cell line, for example, uses the fucose knockout platform technology independently developed by Tianguangshi, see the CHO cell line with the deposit number CGMCC No. 14287 in US Patent No. 10377833B2.

[0108] Another modification of the antibodies herein is polyethylene glycolation (PEGylation). Antibodies can be PEGylated, for example, to increase the biological (e.g., serum) half-life of the antibody. To PEGylate an antibody, the antibody or fragment thereof is typically reacted with polyethylene glycol (PEG), such as a reactive ester or aldehyde derivative of PEG, under conditions such that one or more PEG groups are attached to the antibody or antibody fragment. Preferably, PEGylation is performed by an acylation reaction or an alkylation reaction with a reactive PEG molecule (or a similar reactive water-soluble polymer). The term "polyethylene glycol" as used herein includes any form of PEG used to derivatize other proteins, such as mono(C1-C 10 ) alkoxy- or aryloxypolyethylene glycol or polyethylene glycol maleimide. In certain embodiments, the antibody to be PEGylated is a deglycosylated antibody. Methods for PEGylating proteins are known in the art and can be applied to the antibodies of the present application. See, for example, EPO 154 316 and EP 0 401 384.

[0109] The antibodies of the present application can be characterized by their various physical properties to detect and / or distinguish their species.

[0110] For example, an antibody may contain one or more glycosylation sites in the light chain or heavy chain variable region. These glycosylation sites may increase antibody immunogenicity or alter the antibody pK value due to altered antigen binding (Marshall et al (1972) Annu Rev Biochem 41: 673-702; Gala and Morrison (2004) J Immunol 172: 5489-94; Wallick et al (1988) J Exp Med 168: 1099-109; Spiro (2002) Glycobiology 12: 43R-56R; Parekh et al (1985) Nature 316: 452-7; Mimura et al., (2000) Mol Immunol 37: 697-706). Glycosylation is known to occur in motifs containing the N-X-S / T sequence. In some cases, it is preferred that the B7-H3 antibody does not contain variable region glycosylation. This can be achieved by selecting an antibody that does not contain a glycosylation motif in the variable region or by mutating residues in the glycosylation region.

[0111] In a preferred embodiment, the antibody does not contain an asparagine isomerization site. Deamidation of asparagine may occur in NG or DG sequences, creating an isoaspartic acid residue that introduces a kink into the polypeptide chain and reduces its stability (isoaspartic acid effect).

[0112] Each antibody will have a unique isoelectric point (pI), which generally falls within the pH range of 6-9.5. The pI of IgG1 antibodies generally falls within the pH range of 7-9.5, while the pI of IgG4 antibodies generally falls within the pH range of 6-8. It is speculated that antibodies with pIs outside the normal range may have some unfolded structures and be unstable under in vivo conditions. Therefore, it is preferred that the pI value of the B7-H3 antibody falls within the normal range. This can be achieved by selecting an antibody with a pI within the normal range or by mutating uncharged surface residues.

[0113] On the other hand, the present application provides nucleic acid molecules encoding the heavy chain / light chain variable region or CDR of the antibody or antigen-binding portion thereof of the present application. The nucleic acid can be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form. A nucleic acid is "isolated" or "substantially pure" when purified from other cellular components or other contaminants, such as other cellular nucleic acids or proteins, by standard techniques. The nucleic acid of the present application can be, for example, DNA or RNA, and may or may not contain intron sequences. In a preferred embodiment, the nucleic acid is a cDNA molecule.

[0114] The nucleic acid of the present application can be obtained using standard molecular biology techniques. For antibodies expressed by hybridomas (e.g., hybridomas prepared by transgenic mice carrying human immunoglobulin genes), cDNA encoding the light chain and heavy chain of the antibody prepared by the hybridoma can be obtained by standard PCR amplification or cDNA cloning techniques. For antibodies obtained from immunoglobulin gene repositories (e.g., using phage display technology), nucleic acids encoding such antibodies can be collected from gene banks.

[0115] The preferred nucleic acid molecules of the present application include V encoding B7-H3 monoclonal antibody H and V L Once the sequences encoding V H and V L These DNA fragments can be further manipulated by standard recombinant DNA techniques, such as converting variable region genes into full-length antibody chain genes, Fab fragment genes, or scFv genes. H or V L The term "operably linked" refers to a DNA fragment that is operably linked to another DNA fragment encoding another protein, such as an antibody constant region or a flexible linker. The term "operably linked" means that the two DNA fragments are linked together so that the amino acid sequences encoded by the two DNA fragments are in the reading frame.

[0116] Code V H The isolated DNA of the region can be operably linked to the V H The DNA encoding the heavy chain constant region (C H1 、C H2 and C H3 The heavy chain constant region can be IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM, or IgD, but preferably IgG1 or IgG4. For the Fab fragment heavy chain gene, the V H The DNA of the heavy chain C region can be operably linked to the H1 The constant region of another DNA molecule is attached.

[0117] Code V L The isolated DNA of the region can be operably linked to the V L DNA encoding the light chain constant region C LThe light chain constant region is converted into a full-length light chain gene by using another DNA molecule from the human light chain constant region. The sequences of human light chain constant region genes are known in the art, and DNA fragments comprising these regions can be obtained by standard PCR amplification. In a preferred embodiment, the light chain constant region can be a kappa or lambda constant region.

[0118] To create scFv genes, the V H and V L The DNA fragment can be operably linked to another fragment encoding a flexible linker, such that V H and V L The sequence can be expressed as a continuous single-chain protein, where V H and V L The regions are connected by this flexible linker (see, e.g., Bird et al., (1988) Science 242:423-426; Huston et al., (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883; McCafferty et al., (1990) Nature 348:552-554).

[0119] The monoclonal antibodies of the present application can be prepared using the somatic cell hybridization (hybridoma) technique of Kohler and Milstein (1975) Nature 256:495. Other embodiments for preparing monoclonal antibodies include viral or oncogenic transformation of B lymphocytes and phage display technology. Chimeric or humanized antibodies are also well known in the art. See, for example, U.S. Patents 4,816,567; 5,225,539; 5,530,101; 5,585,089; 5,693,762 and 6,180,370.

[0120] The antibodies or antigen-binding portions thereof of the present application can also be produced in host cell transfectomas using, for example, recombinant DNA technology in combination with gene transfection methods (e.g., Morrison, S. (1985) Science 229:1202). In one embodiment, DNA encoding partial or full-length light and heavy chains obtained by standard molecular biological techniques is inserted into one or more expression vectors such that the genes are operably linked to transcriptional and translational regulatory sequences. In this case, the term "operably linked" refers to the connection of the antibody gene to the vector such that the transcriptional and translational control sequences within the vector perform their intended functions of regulating antibody gene transcription and translation.

[0121] The term "regulatory sequence" includes promoters, enhancers, and other expression control elements (e.g., polyadenylation signals) that control the transcription or translation of the antibody gene. Such regulatory sequences are described, for example, in Goeddel (Gene Expression Technology. Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990)). Preferred regulatory sequences for mammalian host cell expression include viral elements that direct high-level protein expression in mammalian cells, such as promoters and / or enhancers from cytomegalovirus (CMV), simian virus 40 (SV40), adenoviruses, such as the adenovirus major late promoter (AdMLP), and polyomavirus. Alternatively, non-viral regulatory sequences, such as the ubiquitin promoter or the β-globin promoter, may be used. In addition, regulatory elements are composed of sequences from different sources, such as the SRα promoter system, which contains sequences from the SV40 early promoter and the long terminal repeat of human T-cell leukemia virus type 1 (Takebe et al., (1988) Mol. Cell. Biol. 8: 466-472). The expression vector and expression control sequences are selected to be compatible with the expression host cell used.

[0122] The antibody light chain gene and the antibody heavy chain gene can be inserted into the same or different expression vectors. In a preferred embodiment, the variable region is inserted into an expression vector encoding the heavy chain constant region and the light chain constant region of the desired subtype to construct a full-length antibody gene, so that V H With the C in the carrier H Operatively connected, V L With the C in the carrier L Operably connected. Alternatively, the recombinant expression vector can encode a signal peptide that promotes secretion of the antibody chain from the host cell. The antibody chain gene can be cloned into a vector so that the signal peptide is connected to the amino terminus of the antibody chain gene in the reading frame. The signal peptide can be an immunoglobulin signal peptide or a heterologous signal peptide (i.e., a signal peptide from a non-immunoglobulin).

[0123] In addition to the antibody chain genes and regulatory sequences, the recombinant expression vectors of the present application may carry other sequences, such as sequences that regulate the replication of the vector in the host cell (e.g., origin of replication) and selectable marker genes. Selectable marker genes can be used to select host cells into which the vector has been introduced (see, e.g., U.S. Patents 4,399,216; 4,634,665 and 5,179,017). For example, selectable marker genes typically confer drug resistance, such as G418, hygromycin, or methotrexate resistance, to host cells into which the vector has been introduced. Preferred selectable marker genes include the dihydrofolate reductase (DHFR) gene (for methotrexate selection / amplification of dhfr host cells) and the neo gene (for G418 selection).

[0124] For the expression of light and heavy chains, expression vectors encoding the heavy and light chains are transfected into host cells by standard techniques. The term "transfection" in its various forms includes a variety of techniques commonly used to introduce exogenous DNA into prokaryotic or eukaryotic host cells, such as electroporation, calcium phosphate precipitation, DEAE-dextrose transfection, and the like. Although it is theoretically feasible to express the antibodies of the present application in prokaryotic or eukaryotic host cells, it is preferred that the antibodies be expressed in eukaryotic cells, most preferably in mammalian host cells, because eukaryotic cells, particularly mammalian cells, are more likely to assemble and secrete properly folded and immunologically active antibodies than prokaryotic cells.

[0125] Preferred mammalian host cells for expressing the recombinant antibodies of the present application include Slc35C1 gene knockout cell lines, FUT8 knockout cell lines, variant CHO cell lines Lec13, rat hybridoma cell lines YB2 / 0, cell lines containing small interfering RNA specific for the FUT8 gene, cell lines co-expressing β-1,4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II, Chinese hamster ovary (CHO cells) (including dhfr-CHO cells administered with a DHFR selectable marker, described in Urlaub and Chasin, (1980) Proc. Natl. Acad. Sci. USA 77:4216-4220, and the DHFR selectable marker is described, for example, in RJ Kaufman and PA Sharp (1982) J. Mol. Biol. 159:601-621), NSO myeloma cells, COS cells, and SP2 cells. When a recombinant expression vector encoding an antibody gene is introduced into a mammalian host cell, the antibody is prepared by culturing the host cell for a period of time sufficient to allow expression of the antibody in the host cell, or preferably sufficient to allow secretion of the antibody into the culture medium in which the host cell is grown. The antibody can be recovered from the culture medium using protein purification methods.

[0126] The antibody of the present application or its antigen-binding portion thereof can be coupled with therapeutic agent to form immunoconjugate, such as antibody-drug conjugate (ADC). Suitable therapeutic agent includes cytotoxin, alkylating agent, DNA minor groove binding molecule, DNA intercalator, DNA cross-linking agent, histone deacetylase inhibitor, nuclear export inhibitor, proteasome inhibitor, inhibitor of topoisomerase I or II, heat shock protein inhibitor, tyrosine kinase inhibitor, antibiotic and antimitotic agent. In ADC, antibody and therapeutic agent are preferably cross-linked by joint, and this joint can be cut, such as peptide joint, disulfide joint or hydrazone joint. More preferably, joint is peptide joint, such as Val-Cit, Ala-Val, Val-Ala-Val, Lys-Lys, Ala-Asn-Val, Val-Leu-Lys, Ala-Ala-Asn, Cit-Cit, Val-Lys, Lys, Cit, Ser or Glu. ADCs can be prepared as described in U.S. Patents 7,087,600; 6,989,452; and 7,129,261; PCT Publications WO 02 / 096910; WO 07 / 038,658; WO 07 / 051,081; WO 07 / 059,404; WO 08 / 083,312; and WO 08 / 103,693; U.S. Patent Publications 20060024317; 20060004081; and 20060247295.

[0127] On the other hand, the present application relates to a bispecific molecule comprising one or more antibodies of the present application or their antigen-binding portion linked to at least one other functional molecule, such as another peptide or protein (e.g., another antibody or receptor ligand), to generate a bispecific molecule that binds to at least two different binding sites or targeting molecules. The term "bispecific molecule" includes molecules with three or more specificities.

[0128] Bispecific molecules can come in a variety of forms and sizes. At one end of the size spectrum, bispecific molecules maintain the traditional antibody format, except that they have two binding arms, each with a different specificity, instead of having two binding arms with the same specificity. At the other extreme are bispecific molecules composed of two single-chain antibody fragments (scFv) linked by a peptide chain, called Bs(scFv)2 constructs. Bispecific molecules of intermediate size include two different F(ab) fragments connected by a peptide linker. These and other forms of bispecific molecules can be prepared by genetic modification, somatic cell hybridization, or chemical methods. See, for example, Kufer et al, cited supra; Cao and Suresh, Bioconjugate Chemistry, 9(6), 635-644 (1998); and van Spriel et al., Immunology Today, 21(8), 391-397 (2000).

[0129] The present application also provides a chimeric antigen receptor comprising a B7-H3 single-chain antibody scFv, wherein the scFv comprises the heavy chain and light chain CDRs, or the heavy chain and light chain variable regions described in the present application.

[0130] The B7-H3 chimeric antigen receptor may comprise (a) an extracellular antigen binding domain comprising a B7-H3 scFv; (b) a transmembrane domain; and (c) an intracellular signaling domain.

[0131] Oncolytic viruses preferentially infect and kill cancer cells. The antibodies or antigen-binding portions thereof of the present application can be used together with oncolytic viruses. In addition, oncolytic viruses encoding the antibodies or antigen-binding portions thereof of the present application can be introduced into the human body.

[0132] On the other hand, the present application provides a pharmaceutical composition comprising one or more antibodies or antigen-binding portions thereof, antibody or antigen-binding portion encoding vectors, immunoconjugates, immune cells, bispecific antibodies, and / or oncolytic viruses of the present application, formulated together with a pharmaceutically acceptable carrier. The composition may optionally contain one or more other pharmaceutically active ingredients, such as another anti-tumor antibody, or an immune-enhancing antibody, or a non-antibody anti-tumor agent, or an immunopotentiator. The pharmaceutical composition of the present application can be used in combination with, for example, another anticancer agent or another immunopotentiator.

[0133] The pharmaceutical composition may contain any number of excipients. Useful excipients include carriers, surfactants, thickeners or emulsifiers, solid binders, dispersing or suspending agents, solubilizing agents, colorants, flavoring agents, coatings, disintegrants, lubricants, sweeteners, preservatives, isotonic agents, and combinations thereof. The selection and use of suitable excipients are taught in Gennaro, ed., Remington: The Science and Practice of Pharmacy, 20th Ed. (Lippincott Williams & Wilkins 2003).

[0134] Preferably, the pharmaceutical composition is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or push injection). Based on the difference in route of administration, the active ingredient can be wrapped in a material to protect it from the influence of acid and other natural conditions that may inactivate it. "Parenteral administration" refers to a mode different from intestinal and topical, usually carried out by injection, including but not limited to intravenous, intramuscular, intraarterial, intramembranous, intracapsular, intraorbital, intracardial, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, on the dura mater and intrasternal injection and push injection. Alternatively, the antibody of the present application can be administered by non-parenteral route, such as external use, epidermal administration or mucosal administration, such as intranasal, oral, vaginal, rectal, sublingual, or topical.

[0135] Pharmaceutical compositions can be in the form of sterile aqueous solutions or dispersions. They can also be formulated in microemulsions, liposomes, or other ordered structures suitable for high drug concentrations.

[0136] The amount of active ingredient prepared in a single dosage form together with the carrier material will vary depending on the subject being treated and the particular mode of administration, and is essentially the amount of the composition that produces a therapeutic effect. In percentage terms, this amount is about 0.01 to about 99% of the active ingredient combined with the pharmaceutically acceptable carrier.

[0137] The dosage regimen is adjusted to provide the optimal desired response (e.g., a therapeutic response). For example, a bolus may be administered, multiple divided doses may be administered over time, or the dose may be reduced or increased in proportion to the severity of the therapeutic situation. It is particularly advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. A dosage unit form refers to physically discrete units suitable for single administration to a subject; each unit contains a predetermined amount of the active ingredient calculated to produce the desired therapeutic effect together with a pharmaceutical carrier. Alternatively, the antibody may be administered as a sustained-release formulation, in which case the required frequency of administration is reduced.

[0138] For administration of the antibody, the dosage may be about 0.001-100 mg / kg host body weight. An exemplary treatment regimen involves administration once a week. The preferred dosing regimen of the present application B7-H3 includes intravenous administration.

[0139] A "therapeutically effective amount" of the B7-H3 antibody of the present application results in a reduction in the severity of disease symptoms and an increase in the frequency and duration of symptom-free periods. For example, for the treatment of a tumor-bearing subject, a "therapeutically effective amount" preferably inhibits tumor growth by at least about 20%, more preferably by at least about 40%, even more preferably by at least about 60%, and even more preferably by at least about 80%, compared to an untreated subject. A therapeutically effective amount of a therapeutic antibody can reduce tumor size or alleviate symptoms in a subject, which can be a human or another mammal.

[0140] The pharmaceutical composition can be a sustained-release agent, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. See, for example, Sustained and Controlled Release Drug Delivery Systems, JR Robinson, ed., Marcel Dekker, Inc., New York, 1978.

[0141] Pharmaceutical compositions can be administered via medical devices, such as (1) needle-free subcutaneous injection devices (e.g., U.S. Patents 5,399,163; 5,383,851; 5,312,335; 5,064,413; 4,941,880; 4,790,824; and 4,596,556); (2) microinfusion pumps (U.S. Patent 4,487,603); (3) transdermal delivery devices (U.S. Patent 4,486,194); (4) push injection devices (U.S. Patents 4,447,233 and 4,447,224); and (5) osmotic devices (U.S. Patents 4,439,196 and 4,475,196).

[0142] In certain embodiments, the monoclonal antibodies of the present application can be formulated to ensure appropriate in vivo distribution. For example, to ensure that the therapeutic antibodies of the present application cross the blood-brain barrier, the antibodies can be formulated in liposomes, which can also additionally contain targeting functional groups to enhance selective delivery to specific cells or organs. See, e.g., U.S. Patents 4,522,811; 5,374,548; 5,416,016; and 5,399,331; V.V. Ranade (1989) J. Clin. Pharmacol. 29:685; Umezawa et al., (1988) Biochem. Biophys. Res. Commun. 153:1038; Bloeman et al., (1995) FEBS Lett. 357:140; M. Owais et al., (1995) Antimicrob. Agents Chemother. 39:180; Briscoe et al., (1995) Am. J. Physiol. 1233:134; Schreier et al., (1994) J. Biol. Chem. 269:9090; Keinanen and Laukkanen (1994) FEBS Lett. 346:123; and Killion and Fidler (1994) Immunomethods 4:273.

[0143] The pharmaceutical compositions of the present application have various in vitro and in vivo applications, involving, for example, the treatment of cancer, or more generally, for immune enhancement in patients with diseases such as cancer. The pharmaceutical compositions can be administered to human subjects, for example, to inhibit tumor growth in vivo.

[0144] Taking into account the ability of the present application's pharmaceutical composition to inhibit tumor cell proliferation and survival, the present application provides a method for inhibiting tumor cell growth in a subject, including administering the present application's pharmaceutical composition to the subject, so that tumor growth is suppressed in the subject. Non-limiting examples of tumors that can be treated by the present application's antibody include but are not limited to breast cancer, melanoma, prostate cancer, head and neck squamous cell carcinoma, lung cancer, non-small cell lung cancer, central nervous system neuroblastoma, glioblastoma, desmoplastic small round cell tumor, diffuse pontine glioma, medulloblastoma, pancreatic cancer, liver cancer, colorectal cancer, non-Hodgkin's lymphoma, esophageal cancer, ovarian cancer, bladder cancer, small cell carcinoma, endometrial cancer, kidney cancer, gastric cancer, acute myeloid leukemia, hepatocellular carcinoma, hypopharyngeal squamous cell carcinoma, urothelial cell carcinoma, whether primary or metastatic. In addition, refractory or recurrent malignant tumors also may be treated with the present application's pharmaceutical composition. The present application's pharmaceutical composition can also treat autoimmune diseases, such as asthma, etc.

[0145] The pharmaceutical composition of the present application can be used to enhance the immune response in a subject, for example, to activate immune cells such as NK cells, T cells, etc.

[0146] The present application provides a combination therapy in which the pharmaceutical composition of the present application is administered together with one or more other antibodies or non-antibody therapeutic agents, which can effectively inhibit tumor growth in a subject. In one embodiment, the present application provides a method for inhibiting tumor growth in a subject, comprising administering the pharmaceutical composition of the present application and one or more other antibodies, such as PD-1 antibodies, PD-L1 antibodies and / or 4-1BB antibodies to the subject. In certain embodiments, the subject is a human. In another aspect, the present application provides a method for treating cancer, wherein the pharmaceutical composition of the present application is administered together with a chemotherapeutic agent, which may be a cytotoxic agent. Other therapies that can be combined with the pharmaceutical composition of the present application include, but are not limited to, administration of an immunogenic agent, administration of interleukin 2 (IL-2), radiotherapy, surgery, or hormone removal.

[0147] The combination of therapeutic agents discussed herein can be administered simultaneously as a single composition in a pharmaceutically acceptable carrier, or as separate compositions, each agent being in a pharmaceutically acceptable carrier. In another embodiment, the combination of therapeutic agents can be administered sequentially.

[0148] Furthermore, if multiple administrations of the combination therapy are performed and the agents are administered sequentially, the order of sequential administration at each time point can be reversed or remain the same, sequential administration can be combined with simultaneous administration, or any combination thereof.

[0149] The present application is further described by the following examples, which should not be interpreted as limiting. All figures and all references, Genebank sequences, patents and published patent applications cited throughout this application are incorporated herein by reference in their entirety.

[0150] Example

[0151] Example 1. Generation of anti-human B7-H3 monoclonal antibodies

[0152] To generate antibodies against human B7-H3, recombinant human B7-H3 (4Ig) protein (human B7-H3 (4Ig) / B7-H3b protein with a His tag, Cat#: B7B-H52E7, Beijing Biopsies Biotechnology Co., Ltd.) and / or recombinant human B7-H3 (2Ig) protein (human B7-H3 / CD276 protein with a His tag (MALS verified), Cat#: B73-H52E2, Beijing Biopsies Biotechnology Co., Ltd.) were used to immunize B7-H3 RenMab KO mice. RenMab mice have a humanized heavy chain immunoglobulin locus and a humanized kappa chain immunoglobulin locus. The heavy chain immunoglobulin locus contains regions of the antibody heavy chain gene. This locus includes IGHV (variable), IGHD (diversity), IGHJ (joining), and heavy chain constant domain genes. The kappa chain immunoglobulin locus contains genes encoding the antibody light chain (kappa chain). The kappa chain immunoglobulin locus includes IGKV (variable), IGKJ (joining), and light chain constant domain genes. A detailed description of RenMab mice can be found in PCT / CN2020 / 075698, which is incorporated herein by reference in its entirety. B7-H3 RenMab KO mice are obtained by knocking out the RenMab mouse B7-H3 gene, and they do not express functional B7-H3 protein in vivo.

[0153] Mouse immunization

[0154] B7-H3 RenMab KO mice were immunized four times with recombinant human B7-H3 (4Ig) protein. The protein was mixed with adjuvant in a 1:1 ratio and then emulsified. Each animal was injected via the heel and neck. The first immunization was administered with complete Freund's adjuvant (CFA), and the second to fourth immunizations were administered with incomplete Freund's adjuvant (IFA). At least 14 days were allowed between injections.

[0155] In another parallel experiment, recombinant human B7-H3 (4Ig) and recombinant human B7-H3 (2Ig) proteins were cross-immunized. The proteins were mixed with adjuvant in a 1:1 ratio and then emulsified. Each animal was injected via the heel and neck. The first immunization adjuvant was complete Freund's adjuvant (CFA), and the second to fourth immunizations were administered with incomplete Freund's adjuvant (IFA). At least 14 days passed between the two injections.

[0156] Antibody titers can be determined by collecting peripheral blood (serum) and using fluorescence-activated cell sorting (FACS) or ELISA.

[0157] At least 14 days after the fourth immunization, the final booster immunization was performed by intraperitoneal injection of B7-H3 (4Ig) protein and tail vein injection of CHO cells expressing B7-H3 (2Ig) antigen into mice.

[0158] Antibody discovery

[0159] Four days after the last immunization, the mice were killed and antigen-positive B cells were directly isolated from the immunized mice. Plasma cells secreting antigen-specific monoclonal antibodies were identified using an optical flow system (Berkeley Lights Inc.). Antibody variable region sequences were obtained using reverse transcription and PCR sequencing. The heavy and light chain variable regions were cloned into a vector containing a human IgG constant region and a human kappa constant region backbone for expression. The specific binding of the expressed antibodies to B7-H3 was verified using FACS. Exemplary fully human antibodies obtained using this method include 6B5, 10D7, 10F5, 10F7, and 15F11. The sequences and SEQ ID numbers of their heavy and light chain variable regions and CDRs are listed in Tables 1 and 9.

[0160] Antibody construction, expression, and purification

[0161] The antibody expression vector was constructed by inserting the sequences encoding the variable region and the human IgG1 / κ constant region (the amino acid sequences of the heavy chain constant region and the light chain constant region are listed in SEQ ID NOs: 43 and 45, respectively) into the restriction enzyme cleavage sites XhoI / BamHI of pCDNA3.1 (Invitrogen, USA).

[0162] The expression vector PEI obtained above was transfected into HEK-293F cells (Cobioer, China). TM HEK-293F cells were cultured in 293 expression medium (Cat#:12338-018, Gibco, USA) and transfected with each expression vector using polyethyleneimine (PEI) transfection. The DNA:PEI ratio was 1:3, and 1.5 μg of DNA was added per ml of cell culture medium. Transfected HEK-293F cells were cultured at 120 rpm in a 37°C, 5% CO2 incubator. After 10-12 days, the cell culture supernatant was collected, centrifuged at 3500 rpm for 5 minutes, and filtered through a 0.22 μm filter to remove cell debris. Monoclonal antibodies were enriched and purified using a pre-equilibrated Protein-A affinity column (Cat#:17040501, GE, USA) and eluted with elution buffer (20 mM citric acid, pH 3.0-pH 3.5). Antibodies were then stored in PBS (pH 7.0) and their concentrations were determined using a NanoDrop flow cytometer.

[0163] Example 2. Affinity detection of fully human B7-H3 antibodies

[0164] The binding affinity of fully human anti-human B7-H3 antibodies to human B7-H3 (4Ig), human B7-H3 (2Ig), monkey B7-H3 (monkey B7-H3 / CD276 protein with a His tag, Cat#: B73-C52Ha, Beijing Biopsies Biotechnology Co., Ltd.), and mouse B7-H3 protein (mouse B7-H3 / CD276 protein with a His tag, Cat#: B73-M52H4, Beijing Biopsies Biotechnology Co., Ltd.) was measured by surface plasmon resonance (SPR) using a Biacore (Biacore, USA) T200 biosensor equipped with a pre-immobilized Protein A sensor chip. Briefly, anti-human B7-H3 antibody (1 μg / mL) was injected into the Biacore T200 biosensor at 10 μL / min for approximately 20 seconds to achieve the desired protein density (100 ± 30 RU). The antigen protein was then injected at 30 μL / min for 180 seconds at concentrations of 200 nM, 100 nM, 50 nM, 25 nM, 12.5 nM, 6.25 nM, 3.125 nM, 1.5625 nM, 0.78125 nM, and 0 nM, and dissociation was monitored for 600 seconds. Enochumab, an Fc-optimized humanized B7-H3 antibody developed by MacroGenics (see US8802091B2 for the antibody sequence, with the heavy and light chain variable region sequences shown in SEQ ID NOs: 39 and 40, respectively; the heavy chain constant region is an IgG1 constant region with five point mutations F243L / R292P / Y300L / L235V / P396L to enhance ADCC efficacy; the light chain is a kappa chain constant region, with sequences shown in SEQ ID NOs: 44 and 45, respectively), was used as a positive control antibody.

[0165] The data were analyzed using a 1:1 binding fit using Biacore Insight software V2.0.1 5.12933. The association rate (kon) and dissociation rate (koff) were obtained simultaneously. The quotient of the kinetic rate constant (K D =koff / kon) to calculate affinity.

[0166] All antibodies in this application bind to two different spliced ​​forms of human B7-H3 and monkey B7-H3 protein. Antibodies 6B5 and 15F11 also bind to mouse B7-H3 protein. Tables 2 and 3 show the affinity test results of representative antibodies in this application.

[0167] Table 2. Binding affinity of B7-H3 antibodies to human B7-H3 (4Ig) and human B7-H3 (2Ig)

[0168]

[0169] Table 3. Binding affinity of B7-H3 antibodies to monkey B7-H3 and mouse B7-H3

[0170]

[0171] Example 3. Binding Ability of Fully Human B7-H3 Antibodies to B7-H3-Positive Tumor Cells, B7-H3-Negative Tumor Cells, and B7-H3-Positive Normal Cells

[0172] To determine the binding of the fully human B7-H3 antibody of the present application to different types of B7-H3 positive tumor cells, negative tumor cells and B7-H3 positive normal cells, A549 cells (Cat#: CBP60084, Kebai), NCI-H520 cells (Cat#: CBP60139, Kebai), HepG2 cells (Cat#: CBP60199, Kebai), SK-OV-3 cells (Cat#: CBP6029 1, Kebai) and MCF-7 cells (Cat#: CL-0149, Purnosai) were used as representatives of B7-H3-positive tumor cells, Jurkat cells (Cat#: CBP60520, Kebai), Daudi cells (Cat#: CBP60262, Kebai), and Raji cells (Cat#: CBP60272, Kebai) were used as representatives of B7-H3-negative tumor cells (according to literature reports, these three cell types were negative for B7-H3 mRNA), and human prostate smooth muscle cells (Cat#: CC-2587, Lonza), human dermal fibroblasts (Cat#: CC-2511, Lonza), human aortic smooth muscle cells (Cat#: H-6080, Cell Biologics), and human dendritic cells (human PBMCs induced to mature) were used as representatives of normal cells for FACS cell binding assays.

[0173] A549 cells, NCI-H520 cells, Jurkat cells, Daudi cells, and Raji cells were cultured in RPMI1640 medium (Cat#:12-115F, Lonza) supplemented with 10% FBS (Cat#:FND500, Excell) and 1% penicillin / streptomycin (Cat#:SV30010, Hyclone). HepG2 cells and SK-OV-3 cells were cultured in MEM medium (Cat#:12561-056, Gibco) and McCoy's 5A medium (Cat#:16600-082, Hyclone), respectively, both supplemented with 10% FBS (Cat#:FND500, Excell) and 1% penicillin / streptomycin (Cat#:SV30010, Hyclone). MCF-7 cells were cultured in MCF7 cell-specific culture medium (Cat#: CM-0149, Purnocell), and human prostate smooth muscle cells were cultured in SmGM. TM -2 Smooth Muscle Cell Growth Medium Bullet Kit TM Human dermal fibroblasts were cultured according to the instructions (Cat#: CC-3182, Lonza) by FGM. TM -2 Fibroblast Growth Medium Bullet Kit TM Human aortic smooth muscle cells were cultured using smooth muscle cell complete medium (Cat#: CC-3132, Lonza) according to the manufacturer's instructions, and human aortic smooth muscle cells were cultured using smooth muscle cell complete medium (Cat#: M2268, Cell Biologics) according to the manufacturer's instructions.

[0174] Human dendritic cells were obtained by isolating PBMC and inducing them in vitro. Briefly, PBMC (Cat#: PB004F-C, ALLCELLS) were resuspended in RPMI1640 medium and cultured in a 37°C incubator for 2 hours. Adherent cells were collected to obtain isolated monocytes. Monocytes were cultured in RPMI1640 medium supplemented with 100 ng / ml recombinant human GM-CSF (Cat#: 7954-GM, R&D), 100 ng / ml recombinant human IL-4 (Cat#: 6507-IL, R&D), and 10% FBS. After three days, half of the medium was replaced with fresh medium. On day 6 of culture, the culture medium was replaced with a medium containing 100 ng / ml recombinant human GM-CSF, 100 ng / ml recombinant human IL-4, 10 ng / ml rhTNF-α (Cat#: 210-TA-100, R&D), 1000 U / ml rhIL-6 (Cat#: 7270-IL-025, R&D), 1 μg / ml PGE2 (Cat#: 363-24-6, TOCRIS), and 10 ng / ml IL-1β (Cat#: 210-LB-025, R&D). Mature human dendritic cells were obtained after an additional 2-day incubation.

[0175] The binding capacity of B7-H3 antibody to the above cells was tested. Briefly, 10 5 Cells were plated on a 96-well plate and 50 μl of gradiently diluted B7-H3 antibody was added. After incubation at 4°C for 1 hour, the 96-well plate was washed 3 times with PBST. After that, 500-fold diluted PE-goat anti-mouse IgG (Cat#: PA1-86078, Invitrogen) was added. After incubation at 4°C for 1 hour, the 96-well plate was washed 3 times with PBS, and then cell fluorescence was detected using a FACS detector (BD). Ennotuzumab antibody was used as a positive control. The test results of representative B7-H3 antibodies in this application are shown in Figures 1-3.

[0176] As shown in Figure 1, 6B5 and 10D7 bound to various types of B7-H3-positive tumor cells with significantly higher binding affinity than the control antibody Enrobotix. As can be seen in Figure 2, 6B5 and 10D7 showed little binding to B7-H3 mRNA-negative tumor cell lines, with binding affinity significantly lower than that of the control antibody Enrobotix, demonstrating that the antibodies of the present application have better B7-H3 binding specificity. Figure 3 shows that in various human normal B7-H3-positive cells, 6B5 had slightly higher binding affinity than the positive control antibody Enrobotix, while 10D7 had comparable binding affinity to Enrobotix.

[0177] Example 4. Fc modification does not affect the binding of fully human B7-H3 antibodies to B7-H3-positive cells

[0178] The 10D7 and 6B5 heavy and light chain variable regions, along with the human IgG1 / κ constant region (SEQ ID NOs: 43 and 45), were cloned into pCDNA3.1 (Invitrogen, USA) to construct expression vectors, which were then transfected into CHO-K1 cells and SLC35c1 knockout CHO-K1-AF cells, respectively. SLC35c1 knockout CHO-K1-AF cells were constructed by Beijing Tianguangshi Biotechnology Co., Ltd. (for details, see US10377833B2). Proteins expressed by this cell line are essentially free of fucosylation. 10D7 and 6B5 were transiently expressed in CHO-K1 and CHO-K1-AF cells and purified. The antibodies were designated 10D7-WT, 6B5-WT, 10D7-AF (defucosylated), and 6B5-AF (defucosylated). Simultaneously, the 10D7 and 6B5 heavy and light chain variable regions, plus five point-mutated human IgG1 Fc / κ constant regions (SEQ ID NOs: 44 (EU numbering: L235V, F243L, R292P, Y300L, and P396L) and 45), were cloned into pCDNA3.1 to construct expression vectors. These vectors were then transfected into CHO-K1 cells for transient expression. The corresponding antibodies were designated 10D7-Mut and 6B5-Mut. Point mutations and defucosylation of the Fc region were used to enhance ADCC efficacy. Antibody expression and purification followed the procedures described in Example 1.

[0179] The binding of B7-H3 antibody was detected by FACS using HUVEC cells expressing human B7-H3 (Cat#: C-12200, PromoCell, Germany) and NCI-H520 cells. HUVEC cells were cultured in EGM. TM -2 Endothelial Cell Growth Medium-2 BulletKit TM (Cat#: CC-3162, Lonza) and subcultured according to the instructions. For the specific methods of culturing NCI-H520 cells and flow cytometry analysis, see Example 3.

[0180] As shown in Figure 4 , alterations in Fc, whether defucosylation or point mutation, did not affect the binding of B7-H3 antibody to B7-H3-positive cells. 10D7-AF, 10D7-WT, and 10D7-Mut had identical binding affinity to HUVEC (B) and NCI-H520 (D). 6B5-AF, 6B5-WT, and 6B5-Mut also had identical binding affinity to HUVEC (A) and NCI-H520 (C).

[0181] Example 5. ADCC activity of fully human B7-H3 antibodies and activation of immune cells

[0182] The B7-H3 antibody of the present application was further tested for its ability to induce antibody-dependent cellular cytotoxicity (ADCC) on B7-H3-positive tumor cells NCI-H520, B7-H3-positive human umbilical vein endothelial cells HUVEC, and mature dendritic cells (DC), as well as its immune activation effect on NK cells and PBMC, wherein the dendritic cells were induced to differentiate and mature by isolated PBMC, as shown in Example 3.

[0183] Briefly, NCI-H520 cells, HUVEC cells, and DC cells were resuspended in complete RPMI medium and the cell density was adjusted to 1.0 × 10 6 / ml. Cells were labeled with carboxyfluorescein succinimidyl ester (CFSE, Cat#: C34554I, Invitrogen), specifically using 2.5 μM CFSE, and cells were incubated at 37°C for 10 minutes. After labeling, cells were resuspended in RPMI complete medium (RPMI + 10% FBS). NCI-H520 cells, HUVEC cells, DC cells, and effector cells NK92MI-CD16a (Huabo Bio) were centrifuged at 1200 rpm for 5 minutes. These cells were then suspended in ADCC assay medium (MEM medium, Cat#: 12561-056, Gibco; 1% FBS, Cat#: FND500, EX-cell; 1% BSA, Cat#: V900933-1KG, VETEC). Based on cell counts, cell viability was approximately 90%. Adjust the cell density of target cells (NCI-H520 cells, HUVEC cells or DC cells) to 4×10 5 / ml, and the cell density of NK92MI-CD16a was adjusted to 2×10 6 50 μl of each cell type was added to each well of a 96-well plate (effector-target ratio 5:1). The test antibody was added to each well at varying concentrations, resulting in a starting concentration of 50,000 ng / ml. Other final concentrations were diluted 5-fold, for a total of 10 concentrations. The 96-well plate was incubated at 37°C for 4 hours. The cells were washed three times with PBS and then incubated with LIVE / DEAD fixable dead cell dye for 30 minutes at 37°C. The cells were washed three times with PBS, and 2 μl of PE mouse anti-human CD69 antibody (Cat#: 555531, BD) was added. The cells were incubated at room temperature for 30 minutes, centrifuged, and washed three times with PBS. FACS analysis was performed. Cell death rates were calculated for CFSE-positive cells (NCI-H520 cells, HUVEC cells, or DC cells), and the average PE staining fluorescence intensity for CFSE-negative cells (NK92MI-CD16a cells) was calculated. Entortil was used as a positive control.

[0184] The B7-H3 antibody was further analyzed for its ability to induce ADCC against NCI-H520 cells and HUVEC cells by human PBMC, wherein NCI-H520 cells and HUVEC cells were labeled with carboxyfluorescein succinimidyl ester (CFSE, Cat#: C34554I, Invitrogen). Human PBMCs were obtained by density gradient centrifugation using lymphocyte separation fluid and cultured overnight in culture medium (RIPM1640 + 10% FBS + 300 IU IL-2). ADCC effect detection was performed using the LIVE / DEAD fixable dead cell staining kit (Thermo Fisher, USA, Cat#: L34964). Target cells and effector cell PBMCs were centrifuged at 1200 rpm for 5 minutes. The cells were resuspended in ADCC experimental medium (RIPM1640 medium + 1% FBS), and the cell viability was approximately 90% based on cell counting. The target cell density was adjusted to 4×10 5 / ml, and the PBMC cell density was adjusted to 4×10 6 / ml. 50 μl of each (target ratio 10:1) was added to each well of a 96-well plate. Detection antibodies were added to the sample detection wells so that the starting and ending concentration of each antibody was 50,000 ng / ml. Other final concentrations were diluted 5-fold, with 10 concentrations. The 96-well plate was then incubated at 37°C for 24 hours. The supernatant from each well was collected and the IFN-γ concentration was determined by ELISA (Cat#: SIF50, R&D) using the manufacturer's method. The cells on the plate were washed three times with PBS and then incubated with LIVE / DEAD fixable dead cell dye at 37°C for 30 minutes. The cells were washed three times with PBS and detected by FACS. The cell death rate of CFSE-positive cells (NCI-H520 cells or HUVEC cells) was calculated. Entostatin was used as a positive control. The experimental results are shown in Figures 5-8.

[0185] As shown in Figure 5, 10D7-AF and 10D7-Mut elicited significantly stronger ADCC activity against NCI-H520 tumor cells by NK92 than 10D7-WT and the positive control antibody enoxaparin (A). 10D7-AF also exhibited stronger NK cell activation than 10D7-Mut, with higher induction levels of the activation marker CD69 on the NK cell surface (C). Similarly, the ADCC-inducing effects of 6B5-AF and 6B5-Mut were significantly stronger than those of 6B5-WT and the positive control antibody enoxaparin (B). Furthermore, 6B5-AF exhibited stronger NK cell activation than 6B5-Mut, with higher induction levels of CD69 (D). In addition, the positive control antibody Entostatuzumab mediated the killing of NCI-H520 by NK92 at high doses, showing a strong hook effect. That is, after the antibody concentration reached a certain level, the killing effect detected was weakened when the antibody concentration continued to increase. This effect did not appear in 10D7 and 6B5.

[0186] As shown in Figure 6, 10D7-AF and 10D7-Mut elicited significantly greater cytotoxicity against NCI-H520 tumor cells by PBMCs than did 10D7-WT and the positive control antibody Enoxolone (A). This trend was also reflected in the ADCC-inducing effect of 6B5, with 6B5-AF and 6B5-Mut eliciting significantly greater ADCC against NCI-H520 tumor cells than did 6B5-WT and the positive control antibody Enoxolone (B). Similarly, the positive control antibody at high doses induced a strong "hook effect" on PBMC cytotoxicity against NCI-H520, an effect not seen with either 10D7 or 6B5.

[0187] Figure 7 shows that the ability of 6B5-AF and 10D7-AF to induce NK92 to kill HUVEC cells is stronger than that of the positive control antibody enoxaparin (A). In the reaction system with PBMC as effector cells, neither 6B5-AF, 10D7-AF nor enoxaparin induces significant HUVEC cell killing effect (B) or obvious IFN-γ release (C).

[0188] FIG8 shows that the ability of 6B5-AF and 10D7-AF to induce NK92 to kill DC cells is comparable to that of the positive control antibody Entocillin or lower than that of the positive control.

[0189] Example 6. Detection of endocytic effect of fully human B7-H3 antibody

[0190] To verify whether the B7-H3 antibody of the present application can be internalized into cells, experiments were conducted using A549 cells and NCI-H520 cells as endocytosis carriers, with Enostotuzumab-IgG1-Mut and Omburtamab-IgG1 as positive controls. Omburtamab is a radioiodine-labeled anti-human B7-H3 monoclonal antibody developed by Y-mAbs Therapeutics. Omburtamab-IgG1 has the heavy and light chain variable regions set forth in SEQ ID NOs: 41 and 42, the heavy chain constant region is a wild-type IgG1, and the light chain constant region is a kappa constant region sequence, with the amino acid sequences set forth in SEQ ID NOs: 43 and 45, respectively.

[0191] The anti-human B7-H3 antibody to be tested was mixed with pHAb-labeled goat anti-human IgG1 Fc (Cat#: SSA015, Sino Biological Technology Co., Ltd., pHAb-labeled) at a 1:1 ratio and then mixed with 10,000 A549 cells. The final concentration of the B7-H3 antibody and secondary antibody was 25 μg / mL. Human IgG1 protein served as a blank control. The mixture was incubated on ice for 1 hour in the dark. The cells were then washed three times with pre-chilled FACS buffer (90% DMEM + 10% FBS) by centrifugation. The supernatant was removed, pre-warmed complete culture medium was added, and the cells were incubated in a 37°C, 5% CO2 incubator. Cell cultures were removed at 0, 3, 6, and 9 hours and stored on ice in the dark. After all samples were collected, the supernatant was removed by cold centrifugation at 1200 rpm for 3 minutes, and the cells were eluted once with PBS buffer. The cell surface fluorescence signal was measured. Flow cytometer was used to collect various flow cytometric raw data of cells incubated with different antibodies. Based on the raw data, the MFI of fluorescence emitted by different antibodies after binding to cell surface B7-H3 and internalization into the cells was analyzed and derived, and the endocytic MFI curve based on the amount of internalized B7-H3 antibody was plotted.

[0192] Similar to the above method, NCI-H520 cells were used to detect the internalization of anti-human B7-H3 antibody.

[0193] The results are shown in Figure 9. Throughout the entire assay cycle, no endocytosis occurred after incubation with cells alone, cells plus secondary antibody, or cells plus secondary antibody and human IgG1 protein. However, when co-incubated with 6B5, 10D7, 10F5, 10F7, enoxaparin, and omburtamab-IgG1, the MFI increased over time, with significant increases for 10D7, 10F7, and omburtamab-IgG1. These data demonstrate that 6B5, 10D7, 10F5, 10F7, enoxaparin, and omburtamab-IgG1 can all be internalized by NCI-H520 and A549 cells, with 10D7, 10F7, and omburtamab-IgG1 internalized at a faster rate.

[0194] Example 7. Binding epitope analysis of fully human B7-H3 antibodies

[0195] To determine the binding epitope relationships among the anti-human B7-H3 antibodies, surface plasmon resonance (SPR) was used in tandem assays to investigate the inhibitory effect of each anti-human B7-H3 antibody on the binding of the other antibodies. Four anti-human B7-H3 antibodies were tested: 6B5 ("Ab6B5"), 10D7 ("Ab10D7"), 10F5 ("Ab10F5"), and Enoxolone (AbEno).

[0196] HBS-EP + Buffer (10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 150 mM NaCl, 3 mM ethylenediaminetetraacetic acid (EDTA) and 0.05% P20, pH 7.4) was used as the running buffer. Anti-His antibody was immobilized on the surface of S series sensor chip CM5 by amino coupling to produce an anti-His chip. Then, 1 M ethanolamine (pH 8.5) was injected to block the remaining active carboxyl groups on the chip surface, and then HBS-EP was used. + After equilibration in the buffer for 2 hours, recombinant human B7-H3 (4Ig) protein with a His tag (Cat#: B7B-H52E7, Beijing Biopsies Biotechnology Co., Ltd.) was injected into the Biacore 8K biosensor at a rate of 30 μL / min for 50 seconds and captured on the anti-His chip to achieve a protein density of approximately 50 RU.

[0197] A pair of antibodies (both at a concentration of 800 nM) were injected into the chip successively at a rate of 30 μL / min. The binding time of the first injected antibody (analyte 1) was 300 seconds, and the binding time of the second injected antibody (analyte 2) was 300 seconds. After the injection of the antibodies in each analysis cycle, the chip was regenerated twice with glycine buffer (pH 1.7, 30 μL / min, 30 seconds). The same experimental steps were performed for each pair of monoclonal antibodies to obtain the binding inhibition data of each monoclonal antibody on the other antibody. The binding value of each antibody was obtained using Biacore Insight evaluation software. In order to quantify the interference of one antibody on the binding of another antibody, the binding rate was calculated to compare each pair of antibodies. Cluster analysis was performed using statistical software.

[0198] As shown in Figure 10, the four anti-human B7-H3 antibodies were classified into three epitope clusters, among which 6B5 (Ab6B5) and 10F5 (Ab10F5) may have the same or overlapping epitopes, 10D7 (Ab10D7) has a separate epitope, and the epitopes of 6B5 (Ab6B5), 10F5 (Ab10F5) and 10D7 (Ab10D7) overlap with or are different from those of Enozubd (AbEno).

[0199] Example 8. Binding of anti-human B7-H3 antibodies to B7 homologous proteins

[0200] The binding of anti-human B7-H3 antibodies to B7 homologous proteins was measured by SPR using a Biacore (Biacore, USA) T200 biosensor equipped with a pre-immobilized Protein A sensor chip.

[0201] Specifically, 1 μg / mL of anti-human B7-H3 antibody was captured at a flow rate of 10 μL / min, and 200 nM, 100 nM, 50 nM, 25 nM, 12.5 nM, 6.25 nM and 0 nM of recombinant human proteins CD80 (human B7-1 / CD80 protein with His tag, Cat#: B71-H5228, Beijing Biopsies Biotechnology Co., Ltd.), CD86 (human B7-2 / CD86 protein with His tag, Cat#: CD6-H5223, Beijing Biopsies Biotechnology Co., Ltd.), PDL2 (human PD-L2 / B7-DC protein with His tag, Cat#: PD2-H5220, Beijing Biopsies Biotechnology Co., Ltd.), PDL1 (human PD-L1 / B7-H1 protein with His tag, Cat#: PD1-H 5229, Beijing Biopsies Biotechnology Co., Ltd.), B7-H2 (human B7-H2 / ICOSLG protein with His tag, Cat#: B72-H5221, Beijing Biopsies Biotechnology Co., Ltd.), B7-H3(4Ig) (Cat#: B7B-H52E7, Beijing Biopsies Biotechnology Co., Ltd.), B7-H4 (human B7-H4 protein with His tag (MALS verified), Cat#: BH7-HM174, Kaika Biotechnology (Shanghai) Co., Ltd.), B7-H5 (human B7-H5 / Gi24 / VISTA protein with His tag (MALS verified), Cat#: B75-H52H0, Beijing Biopsies Biotechnology Co., Ltd.), B7-H6 (human B7-H6 / NCR3LG1 protein with His tag, Cat#: B71-H5228, Beijing Biopsies Biotechnology Co., Ltd.), and B7-H7 (human B7-H7 / HHLA2 protein with a His tag (MALS-verified), Cat#: B77-H52H5, Beijing Biopsies Biotechnology Co., Ltd.) were injected at 30 μL / min for 180 seconds. Dissociation was monitored for 600 seconds. The generated data were analyzed using Biacore 8k Evaluation Software 3.0 to obtain binding response values. Protein concentration-binding response correlation curves were plotted to confirm cross-reactivity of the anti-human B7-H3 antibody with B7 family proteins.

[0202] The results are summarized in Table 4. Similar to Entozumab, 6B5, 10D7, and 10F5 antibodies did not bind to recombinant human CD80, CD86, PDL2, PDL1, B7-H2, B7-H3, B7-H4, B7-H5, B7-H6, and B7-H7, but specifically bound to recombinant human B7-H3. The results of 6B5 binding to recombinant human proteins are shown in Figure 11. The binding response values ​​of each antibody at 200 nM of recombinant human protein are summarized in Table 4 below.

[0203] Table 4. Binding of fully human B7-H3 antibodies to B7 homologous proteins

[0204]

[0205] Example 9. In vivo anti-tumor effect of fully human anti-human B7-H3 antibodies

[0206] The in vivo anti-tumor activity of antibodies 6B5, 10D7, and 10F5, along with the positive control antibody Entostatin, was investigated. To better demonstrate the biological effects of the antibody variable regions, the Fc region of all antibodies was selected to be human IgG1, with five point mutations (EU numbering: L235V, F243L, R292P, Y300L, and P396L, SEQ ID NO: 44) to enhance ADCC.

[0207] In the first experiment, B7-H3 humanized mice (Cat#: 110028, Biocytogen) were injected subcutaneously on one side of the abdomen with 2×10 5 EL4 cells overexpressing human B7-H3. When the tumor grows to 90-120 mm 3 At 37 pm, the animals were randomly divided into three groups (n = 8 / group) and intraperitoneally injected with PBS (G1), Enostotuzumab (G2), and 10F5-Mut (G3). The administration frequency was twice a week for a total of 6 doses, with a dose of 10 mg / kg. The day of grouping was designated as day 0, and drug administration began on this day.

[0208] In another experiment, B7-H3 humanized mice were treated with B7-H3 when tumors grew to 90-120 mm. 3 At 4 pm, the animals were randomly divided into four groups (n = 8 / group) and intraperitoneally injected with PBS (G1), Enostotuzumab (G2), 6B5-Mut (G3), and 15F11-Mut (G4), respectively. The dosing frequency and dosage were the same as above. The day of grouping was designated as day 0, and dosing began on this day.

[0209] During the experimental period, the mice were weighed and the tumor volume was measured twice a week. The tumor volume was calculated as V = (length × width 2 ) / 2. Tumor growth inhibition rate TGI (%) = [1-(Ti-T0) / (Vi-V0)]×100, where Ti is the average tumor volume of the treatment group on day i, T0 is the average tumor volume of the treatment group on day 0, Vi is the average tumor volume of the control group on day i, and V0 is the average tumor volume of the control group on day 0.

[0210] Throughout the experimental period, all animals in each group survived and remained in good health. Compared to the control group, the body weight of the treated mice did not change significantly (P>0.05). At grouping (day 0), the average body weight of each group ranged from 19.3 to 19.5 g. By the end of the experiment (day 17 after grouping for the first experiment and day 20 after grouping for the second experiment), the average body weight ranged from 19.8 to 20.9 g, with a body weight change of 103.2% to 111.1%. The results demonstrate that the anti-human B7-H3 antibodies tested were well tolerated by mice, and all antibodies were non-toxic to mice.

[0211] Figure 12 shows the changes in tumor volume in each group of mice. It can be seen that compared with the control group, all anti-human B7-H3 antibodies slowed or inhibited tumor growth to varying degrees, with 10F5-Mut (A), 6B5-Mut, and 15F11-Mut (B) showing stronger anti-tumor effects than the positive control, Enoxolone.

[0212] Tables 5 and 6 list the main data and analysis results during the experiment, including the tumor volume at the time of grouping and 7 days / 14 days after grouping, the tumor volume at the end of the experiment, the survival of mice, the tumor (volume) inhibition rate (TGI TV The data showed that 6B5-Mut, 15F11-Mut, and 10F5-Mut all significantly inhibited tumor growth, with 10F5-Mut showing the best anti-tumor effect, followed by 15F11-Mut.

[0213] Table 5. Summary of the in vivo anti-tumor effects of the fully human anti-human B7-H3 antibody 10F5-Mut

[0214]

[0215] Table 6. Summary of the in vivo anti-tumor effects of fully human anti-human B7-H3 antibodies 6B5-Mut and 15F11-Mut

[0216]

[0217] Example 10. Cross-staining of fully human anti-human B7-H3 antibodies with normal human tissues

[0218] The cross-reactivity of the fully human anti-human B7-H3 antibody 6B5-AF with 35 frozen normal human tissues (each tissue was derived from three different individuals) was evaluated using streptavidin-biotin-conjugated immunohistochemical staining. Entocilizumab was used as a control antibody. The human tissues are shown in Table 7.

[0219] Immunohistochemical staining method: Frozen sections were air-dried at room temperature and washed with PBST for 5–10 min; 0.3% hydrogen peroxide / anhydrous methanol solution was added and reacted at room temperature for 10–15 min, and washed three times with PBST; avidin was added and reacted at room temperature for 10–15 min, and washed three times with PBST; d-biotin solution was added and reacted at room temperature for 10–15 min, and washed three times with PBST; blocking goat serum (working solution) was added and reacted at room temperature for 10–15 min, then discarded; primary antibody (enotocillin-biotin, 6B5-AF-biotin, human IgG1 / κ isotype control-biotin) or PBST was added and reacted at room temperature for 10–15 min, and washed three times with PBST; streptavidin-peroxidase was added and incubated at room temperature for 10–15 min, and washed three times with PBST; DAB was used for color development, hematoxylin was used for counterstaining, and the sections were dehydrated in graded alcohols and then to xylene; the sections were mounted with medium and air-dried before microscopic examination.

[0220] Table 7. 35 types of normal human frozen tissues

[0221] Adrenal glands, aorta, bladder, blood cells, bone marrow, breast, cerebellum, brain, colon, duodenum, eyes, esophagus, fallopian tubes, stomach, heart, kidneys, liver, lungs, lymph nodes, ovaries, pancreas, parathyroid gland, pituitary gland, placenta, prostate, skin, spinal cord, spleen, skeletal muscle, testicles, thymus, thyroid gland, ureters, cervix, endometrium

[0222] Staining results were observed microscopically, and the level of tissue-antibody binding was determined based on the staining. Staining results were scored based on both staining intensity and the percentage of expressing cells (positive cell staining intensity: 0 = no cell staining; 1 = faint or unclear staining; 2 = weak positive staining; 3 = moderate positive staining; 4 = strong positive staining; M = tissue missing or not applicable. Percentage of positive cells in the same cell group: 0 = no cell staining; 1 = less than 25% of the same cell group; 2 = 25%-50% of the same cell group; 3 = 50%-75% of the same cell group; 4 = greater than 75% of the same cell group; M = tissue missing or not applicable). Tissues that showed no positive staining signals with any of the primary antibodies (enotoxin-biotin, 6B5-AF-biotin, human IgG1 / κ isotype control-biotin) and PBST were not included in the analysis. The scoring information for tissues with positive staining signals is summarized in Table 8.

[0223] The human tissue staining results in Table 8 demonstrate that the fully human anti-human B7-H3 antibody 6B5-AF and Enoxolone exhibit consistent tissue-specific staining. Specifically, 24 of the 35 normal human tissues tested showed negative staining, with only 11 exhibiting weak binding. Furthermore, due to the differences in the binding epitopes of 6B5-AF and Enoxolone for the B7-H3 antigen, the intensity of staining varied slightly in some positively staining tissues. As shown in Table 8, compared to Enoxolone, 6B5-AF exhibited slightly stronger staining in the pituitary gland and slightly weaker staining in the thymus, cervix, and endometrium.

[0224] Figure 13 shows representative tissue staining results. Figures 1-1, 2-1, 3-1, and 4-1 show the staining of enoxaparin in the spleen, skeletal muscle, adrenal gland, and bladder; and Figures 1-2, 2-2, 3-2, and 4-2 show the staining of 6B5-AF in the spleen, skeletal muscle, adrenal gland, and bladder.

[0225] Table 8. Summary of positively stained tissue results

[0226]

[0227] a: Positive cell staining intensity - the proportion of positive cells in the same cell type: Positive cell staining intensity: 0 = no cell staining; 1 = faint or unclear staining; 2 = weak positive staining; 3 = moderate positive staining; 4 = strong positive staining; M = missing tissue or not applicable. Positive cell proportion in the same cell type: 0 = no cell staining; 1 = the proportion of positive cells in the same cell type is less than 25%; 2 = the proportion of positive cells in the same cell type is 25%-50%; 3 = the proportion of positive cells in the same cell type is 50%-75%; 4 = the proportion of positive cells in the same cell type is greater than 75%; M = missing tissue or not applicable.

[0228] The sequences mentioned in this application are summarized in Table 9.

[0229] Table 9. Sequence

[0230]

[0231]

[0232]

[0233]

[0234]

[0235]

[0236] ***

[0237] Although the present invention has been described in conjunction with one or more embodiments, it should be understood that the invention is not limited to these embodiments, and the above description is intended to cover all other alternatives, modifications and equivalents included in the spirit and scope of the appended claims. All documents cited herein are fully incorporated herein by reference.

Claims

1. An isolated monoclonal antibody or antigen-binding portion thereof that binds to B7-H3, comprising i) a heavy chain variable region, the heavy chain variable region comprising a VH CDR1 region, a VH CDR2 region, and a VH CDR3 region, wherein: the VH CDR1 region, the VH CDR2 region, and the VH CDR3 region comprise an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to (1) SEQ ID NOs: 1, 2, and 3; (2) SEQ ID NOs: 1, 7, and 8; (3) SEQ ID NOs: 12, 13, and 14; (4) SEQ ID NOs: 18, 19, and 20; or (5) SEQ ID NOs: 23, 24, and 25, respectively; and / or ii) a light chain variable region comprising a VL CDR1 region, a VL CDR2 region, and a VL CDR3 region, wherein the VL CDR1 region, the VL CDR2 region, and the VL CDR3 region comprise an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to (1) SEQ ID NOs: 4, 5, and 6; (2) SEQ ID NOs: 9, 10, and 11; (3) SEQ ID NOs: 15, 16, and 17; (4) SEQ ID NOs: 9, 21, and 22; or (5) SEQ ID NOs: 26, 27, and 28, respectively.

2. The isolated monoclonal antibody or antigen-binding portion thereof of claim 1 , wherein the heavy chain variable region comprises an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NOs: 29, 31, 33, 35 or 37.

3. The isolated monoclonal antibody or antigen-binding portion thereof according to claim 1, wherein The light chain variable region comprises an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NOs:30, 32, 34, 36 or 38.

4. The isolated monoclonal antibody or antigen-binding portion thereof of claim 2, wherein the heavy chain variable region and the light chain variable region comprise an amino acid sequence set forth in (1) SEQ ID NOs: 29 and 30; (2) SEQ ID NOs: 31 and 32; (3) SEQ ID NOs: 33 and 34; (4) SEQ ID NOs: 35 and 36; or (5) SEQ ID NOs: 37 and 38, respectively, that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to (1) SEQ ID NOs: 29 and 30; (2) SEQ ID NOs: 31 and 32; (3) SEQ ID NOs: 33 and 34; (4) SEQ ID NOs: 35 and 36; or (5) SEQ ID NOs: 37 and 38.

5. An isolated monoclonal antibody or antigen-binding portion thereof that binds to B7-H3, comprising i) a heavy chain variable region, the heavy chain variable region comprising a VH CDR1 region, a VH CDR2 region, and a VH CDR3 region, wherein: The VH CDR1, VH CDR2 and VH CDR3 regions are identical to the VH CDR1, VH CDR2 and VH CDR3 regions of the selected VH sequence, respectively, and / or ii) a light chain variable region comprising a VL CDR1 region, a VL CDR2 region, and a VL CDR3 region, wherein the VL CDR1 region, the VL CDR2 region, and the VL CDR3 region are identical to the VL CDR1 region, the VL CDR2 region, and the VL CDR3 region of a selected VL sequence, respectively; wherein the selected VH sequence and the selected VL sequence are one of the following: (1) the selected VH sequence and the selected VL sequence are SEQ ID NOs: 29 and 30, respectively; (2) the selected VH sequence and the selected VL sequence are SEQ ID NOs: 31 and 32, respectively; (3) the selected VH sequence and the selected VL sequence are SEQ ID NOs: 33 and 34, respectively; (4) the selected VH sequence and the selected VL sequence are SEQ ID NOs: 35 and 36, respectively; (5) The selected VH sequence and the selected VL sequence are SEQ ID NOs: 37 and 38, respectively.

6. The isolated monoclonal antibody or antigen-binding portion thereof according to any one of claims 1 to 5, comprising a heavy chain constant region and a light chain constant region, wherein the heavy chain constant region is a human IgG1 constant region and the light chain constant region is a human kappa constant region.

7. The isolated monoclonal antibody or antigen-binding portion thereof according to claim 6, wherein the heavy chain constant region comprises the amino acid sequence shown in SEQ ID NO: 44, and the light chain constant region comprises the amino acid sequence shown in SEQ ID NO:

45.

8. The isolated monoclonal antibody or antigen-binding portion thereof according to any one of claims 1 to 7, which is a defucosylated monoclonal antibody or antigen-binding portion thereof.

9. The isolated monoclonal antibody or antigen-binding portion thereof according to any one of claims 1 to 8, which (a) binds to human B7-H3; (b) binds to monkey B7-H3; (c) binds to mouse B7-H3; (d) binds to B7-H3-positive cells; (e) is capable of activating immune cells; (f) is capable of inducing ADCC against B7-H3-positive cells; and / or (g) has an in vivo anti-tumor effect.

10. A bispecific molecule, immunoconjugate, chimeric antigen receptor, genetically modified T cell receptor, or oncolytic virus comprising the isolated monoclonal antibody or antigen-binding portion thereof of any one of claims 1-9.

11. A nucleic acid encoding the isolated monoclonal antibody or antigen-binding portion thereof of any one of claims 1-9.

12. A pharmaceutical composition comprising the isolated monoclonal antibody or antigen-binding portion thereof according to any one of claims 1 to 9, and a pharmaceutically acceptable carrier.

13. Use of the isolated monoclonal antibody or antigen-binding portion thereof according to any one of claims 1 to 9, or the pharmaceutical composition according to claim 11, in the preparation of a medicament for treating a B7-H3-related disease. The use according to claim 13 , wherein the B7-H3 related disease is a tumor.

15. The method of claim 14, wherein the tumor is selected from the group consisting of breast cancer, melanoma, prostate cancer, head and neck squamous cell carcinoma, lung cancer, non-small cell lung cancer, central nervous system neuroblastoma, glioblastoma, desmoplastic small round cell tumor, diffuse pontine glioma, medulloblastoma, pancreatic cancer, liver cancer, colorectal cancer, non-Hodgkin's lymphoma, esophageal cancer, ovarian cancer, bladder cancer, small cell carcinoma, endometrial cancer, renal cancer, gastric cancer, acute myeloid leukemia, hepatocellular carcinoma, hypopharyngeal squamous cell carcinoma, and urothelial carcinoma.

16. Use of the isolated monoclonal antibody or antigen-binding portion thereof according to any one of claims 1 to 9, or the pharmaceutical composition according to claim 11, in the preparation of a medicament for enhancing an immune response.